TW201600118A - Application of surfactin to cosmetic - Google Patents

Application of surfactin to cosmetic Download PDF

Info

Publication number
TW201600118A
TW201600118A TW103122443A TW103122443A TW201600118A TW 201600118 A TW201600118 A TW 201600118A TW 103122443 A TW103122443 A TW 103122443A TW 103122443 A TW103122443 A TW 103122443A TW 201600118 A TW201600118 A TW 201600118A
Authority
TW
Taiwan
Prior art keywords
surface element
preparing
composition
fatty acid
iso
Prior art date
Application number
TW103122443A
Other languages
Chinese (zh)
Other versions
TWI580440B (en
Inventor
zhen-gang Lu
xin-mei Wang
Xuan-Rui Xu
Original Assignee
Umo Internat Co Ltd
zhen-gang Lu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Umo Internat Co Ltd, zhen-gang Lu filed Critical Umo Internat Co Ltd
Priority to TW103122443A priority Critical patent/TWI580440B/en
Priority to CN201510369154.2A priority patent/CN105213210B/en
Publication of TW201600118A publication Critical patent/TW201600118A/en
Application granted granted Critical
Publication of TWI580440B publication Critical patent/TWI580440B/en

Links

Landscapes

  • Cosmetics (AREA)

Abstract

This invention relates to a surfactin which is a biosurfactant generated by a microorganism- Bacillus subtilis. The surfactin is a natural cycloaliphatic peptide composed of seven amino acids to form a ring-shaped structure. Furthermore, the surfactin has functions of skin aging resistance, wrinkle resistance, skin penetration capability for enhancement of cosmetic (transdermal penetration enhancer), foaming agent, and emulsifier.

Description

表面素於化妝品上之應用 Surface is applied to cosmetics

本發明係關於表面素的應用方法,特別指表面素於化妝品上之應用方法。 The invention relates to a method for applying a surface element, in particular to a method for applying a surface element to cosmetics.

1. 人類皮膚結構及其老化因子1. Human skin structure and its aging factor

皮膚為人體表面主要器官,厚度因部位、年齡及性別會有所不同;且皮膚主要功能為人體第一道屏障,可避免人體內部組織直接受到外在環境因子的損害,如:紫外線照射、溫度變化、濕度變化、懸浮微粒的傷害以及病毒或細菌直接進入人體,因此皮膚容易受到外界因子刺激而啟動老化機制代謝已損傷的細胞。 The skin is the main organ on the surface of the human body. The thickness varies depending on the location, age and gender. The main function of the skin is the first barrier of the human body, which can prevent the internal tissues of the human body from being directly damaged by external environmental factors, such as ultraviolet radiation and temperature. Changes, changes in humidity, damage from aerosols, and viruses or bacteria directly into the body, so the skin is susceptible to external factors that trigger the aging mechanism to metabolize damaged cells.

(1)細胞老化及基因缺損 (1) Cell aging and gene defects

老化作用從細胞開始逐漸影響至組織與器官,使各部分組織器官結構與功能逐漸衰退。在Leonard Hayflick於1963年之研究中,將凍存之人體分離細胞加以培養進行繼代實驗,發現細胞分裂一定次數後發生了形變;由結果發現人體細胞有其分裂上限次數,細胞約分裂50次後其分裂速率及外觀皆會改變,產生不規則的分裂方式,造成粒狀型、扭曲型等不正常之細胞外觀使細胞凋亡;此研究認為生物體生長週期於受精卵時就已決定,事先就已經設定一生物體之生命時鐘,以人類來說,細胞分裂50次,大約可達120年。由於人體並無端粒酶可將細胞複製時所缺失的片段重新複製,致使經多次細胞複製、分裂過程中基因受損,而使得細胞週期有其限制,該限制又稱為Glass Ceiling,此一老化為不可逆且無法避免之過程。 The aging effect gradually affects the tissues and organs from the beginning of the cells, causing the structure and function of various parts of the tissues to gradually decline. In Leonard Hayflick's 1963 study, cryopreserved human isolated cells were cultured for subsequent experiments, and it was found that the cells were deformed after a certain number of divisions; it was found that the human cells had their upper limit of the number of divisions, and the cells split about 50 times. After that, the rate of splitting and appearance will change, resulting in irregular splitting mode, resulting in abnormal cell appearance such as granular and distorted cells, causing apoptosis; this study suggests that the growth cycle of the organism is determined at the time of fertilized eggs. The life clock of an organism has been set in advance. For humans, the cell divides 50 times, about 120 years. Since the human body does not have telomerase to re-copy the fragments deleted when the cells replicate, resulting in damage to the cells during multiple cell replication and division, the cell cycle has its limitation. This limitation is also called Glass Ceiling. Aging is an irreversible and unavoidable process.

(2)紫外線 (2) UV

皮膚與其他器官都會隨著時間而老化,但較不同的地方是皮膚於日常生活中會受到環境因子的刺激,而使皮膚老化較人體其他組織與器官也較為劇烈。在眾多環境老化因子中,以紫外線(ultraviolet,UV)照射最具影 響力;紫外線波長範圍10~400nm,能量範圍為3eV至124eV,依波長可分為三種紫外線階層:(1)長波紫外線(UV-A),其波長介於315~400nm,可直接穿透地球大氣層照射至地表,並可穿透皮膚真皮層,造成皮膚黑斑、老化及皺紋,其穿透力為三種波長中最強者;(2)中波紫外線(UV-B)波長介於280~315nm,會造成皮膚紅腫、熱、痛,嚴重甚至脫皮或者類似灼傷的症狀,照射至地球時會被平流層中的臭氧層吸收,只有極少部分會通過臭氧層到達地表;(3)短波紫外光(UV-C)波長介於100~280nm,能量最強並有相當危險的傷害能力,但因其波長短會於大氣層被吸收,只有小於總太陽光的0.1%能到達地表,且一般遮蔽防曬及玻璃屏障就可有效阻擋。有研究發現UV-A對於人類皮膚成纖維母細胞中會誘發基質金屬蛋白酶的產生,基質金屬蛋白酶家族會將皮膚膠原蛋白、彈性蛋白及細胞間基質等物質分解,使皮膚進行老化;UV-A會迫使細胞內自由基濃度提高,其濃度過高亦會使細胞提早老化更甚者細胞凋亡。 Skin and other organs will age over time, but the difference is that the skin will be stimulated by environmental factors in daily life, and the skin will age more intensely than other tissues and organs. Among the many environmental aging factors, ultraviolet rays (UV) are the most visible Loudness; ultraviolet wavelength range of 10~400nm, energy range from 3eV to 124eV, can be divided into three kinds of ultraviolet rays according to wavelength: (1) long-wave ultraviolet (UV-A), its wavelength is between 315~400nm, can directly penetrate the earth The atmosphere is exposed to the surface and penetrates the dermis layer of the skin, causing dark spots, aging and wrinkles on the skin. Its penetrating power is the strongest among the three wavelengths; (2) The UV-B wavelength is between 280 and 315 nm. It can cause redness, heat, pain, severe skin peeling or similar burns. When exposed to the earth, it will be absorbed by the ozone layer in the stratosphere. Only a small part will reach the surface through the ozone layer. (3) Short-wave ultraviolet light (UV- C) The wavelength is between 100 and 280 nm. It has the strongest energy and is quite dangerous. However, because its wavelength is short, it will be absorbed in the atmosphere. Only less than 0.1% of the total sunlight can reach the surface, and the sunscreen and glass barrier are generally shielded. Can effectively block. Studies have found that UV-A induces the production of matrix metalloproteinases in human skin fibroblasts. The matrix metalloproteinase family decomposes skin collagen, elastin and intercellular matrix to cause skin aging; UV-A It will force the concentration of free radicals in the cells to increase, and the excessive concentration will also cause the cells to age prematurely and even more.

(3)自由基 (3) Free radicals

自由基(Free radical)理論是目前科學界最為一致認同的老化理論,由1954年美國林肯大學醫學院Denham Harmam M.D.提出但並未受到重視,二十年後自由基理論才逐漸被接受,如今已成為老化理論的主流之一,Denham Harmam並於1995年榮獲提名諾貝爾醫學獎。正常原子是具有成對的電子,而自由基是含有不成對電子的氧原子物質;電子於不成對的狀態下極度不穩定,故自由基會將正常原子的電子移轉,使細胞構成基質發生改變,並造成細胞死亡。 The theory of free radicals is the most widely accepted theory of aging in the scientific community. It was proposed by Denham Harmam MD of the University of Lincoln Medical School in 1954 but has not received much attention. After 20 years, the theory of free radicals has gradually been accepted. One of the mainstreams of aging theory, Denham Harmam was nominated for the Nobel Prize in Medicine in 1995. A normal atom has a pair of electrons, and a radical is an oxygen atom substance containing an unpaired electron; the electron is extremely unstable in an unpaired state, so the radical will transfer the electron of the normal atom, causing the cell to form a matrix. Change and cause cell death.

自由基的重要來源除了自身新陳代謝或合成營養素之外,其導致老化來原為環境污染、紫外線、放射線、吸煙、殺蟲劑及許多化學藥品,尤其是環境污染(汽車的廢氣,工廠排放的SO2)都會增加體內大量有害自由基。 An important source of free radicals, in addition to its own metabolism or synthetic nutrients, causes aging to be environmental pollution, ultraviolet rays, radiation, smoking, pesticides and many chemicals, especially environmental pollution (automobile exhaust, factory-emitted SO) 2 ) will increase a lot of harmful free radicals in the body.

自由基攻擊可分成細胞膜損害及DNA損害。對人類細胞而言,含氧的自由基包括有超氧陰離子O2-、過氧化氫H2O2、氫氧基自由基OH-等,都統稱為活性氧分子;過剩的自由基容易攻擊細胞膜上不飽和脂肪酸。當自由基攻擊細胞膜上不飽和脂肪時,形成脂肪過氧化酶(lipid peroxidase),並氧化血管內壁低密度膽固醇並且抑制前列腺素合成酶(prostacycline Synthetase),造成動脈硬化、糖尿病、關節炎、白內障、老化、冠狀動脈疾病等。若自由基深入到細胞核攻擊DNA,使得遺傳訊息改變進而導致癌症;此外,自由基可誘導老化基因並促進老化作用發生,研究指出約80%~90%的老化性、退化性疾病與自由基有關,其中包括癌症、老人癡呆症、帕金森氏症、肌肉營養不良、皮膚黑斑沈積、皺紋生成、黃班、退化心臟病、中風、潰瘍、類風濕性關節炎及多發性硬化等。 Free radical attack can be divided into cell membrane damage and DNA damage. For human cells, oxygen-containing free radicals include superoxide anion O 2 -, hydrogen peroxide H 2 O 2 , hydroxyl radical OH-, etc., all of which are collectively referred to as reactive oxygen molecules; excess free radicals are easily attacked Unsaturated fatty acids on the cell membrane. When free radicals attack unsaturated fat on the cell membrane, they form lipid peroxidase, oxidize low-density cholesterol in the blood vessel wall and inhibit prostacycline synthetase, causing arteriosclerosis, diabetes, arthritis, cataract , aging, coronary artery disease, etc. If free radicals penetrate deep into the nucleus to attack DNA, genetic information changes and lead to cancer; in addition, free radicals can induce aging genes and promote aging, and studies indicate that about 80% to 90% of aging and degenerative diseases are related to free radicals. These include cancer, Alzheimer's disease, Parkinson's disease, muscular dystrophy, skin dark spot deposition, wrinkle formation, yellow shift, degenerative heart disease, stroke, ulcer, rheumatoid arthritis and multiple sclerosis.

細胞對自由基之防禦機制:由細胞合成的各種抗氧化酶,如麩胱甘肽過氧化酵素(glutathione Peroxidase,GPx)、超氧歧化酶(superoxide Dismutase,SOD)等酵素和穀胱甘肽(Glutathione,GSH),能清除超氧陰離子等體內自然產生的物質;研究報告指出長壽動物體內的SOD含量比較高,而人類是目前所知體內SOD含量最高的動物。年長老化、體質改變、環境因素等,皆可能使體內抗氧化酶出現不足狀況進而導致老化。 The defense mechanism of cells against free radicals: various antioxidant enzymes synthesized by cells, such as glutathione peroxidase (GPx), superoxide dismutase (SOD) and other enzymes and glutathione ( Glutathione, GSH), can remove superoxide anion Naturally produced substances in the body; the research report indicates that the SOD content in long-lived animals is relatively high, and humans are currently the animals with the highest SOD content in the body. Older aging, physical changes, environmental factors, etc., may cause the lack of antioxidant enzymes in the body and lead to aging.

(4)發炎反應 (4) Inflammatory response

發炎反應為當組織受傷或感染時產生的反應。首先肥大細胞(Mast cell)會到達組織,並會附著在內皮細胞釋放出: An inflammatory response is a response that occurs when a tissue is injured or infected. First, the mast cells reach the tissue and attach to the endothelial cells to release:

(1)組織胺(Histamine):胺基酸的衍生物,會使微血管(capillary)通透性增加,局部血管擴張,使血漿(plasma)及吞噬細胞等物質能夠通過,並造成癢及過敏反應。 (1) Histamine: a derivative of amino acid, which increases the permeability of microvessels, expands local blood vessels, allows passage of substances such as plasma and phagocytic cells, and causes itching and allergic reactions. .

(2)腫瘤壞死因子(Tumor Necrosis Factor,TNF):細胞素(cytokine)會殺死目標細胞並活化免疫系統,使淋巴細胞加速增殖且阻止病原體的增殖,並可吸引吞噬細胞過來。 (2) Tumor Necrosis Factor (TNF): Cytokine kills target cells and activates the immune system, accelerates proliferation of lymphocytes and prevents the proliferation of pathogens, and attracts phagocytic cells.

(3)前列腺素(Prostaglandin):使微血管擴張,導至於膨脹壓迫神經末梢引發疼痛,在發炎反應過後會產生膿(pus),膿由死細胞及體液構成,通常會被巨噬細胞消化。 (3) Prostaglandin (Prostaglandin): causes microvessels to dilate, leading to swelling and compression of nerve endings causing pain. After the inflammatory reaction, pus is formed. The pus is composed of dead cells and body fluids, and is usually digested by macrophages.

特定的細胞因子就會活化自身環氧化酵素(cyclooxygenase,COX),其中包括COX-1及COX-2兩大類。COX會使花生四烯酸大量轉變為PGE 2和PGF 2α等前列腺素。近期研究發現,在 大多數正常組織都沒有發現COX-2的存在,但是確可在各種癌症病人中檢測出來,這顯示了COX-2在腫瘤病患中的重要性。另,COX-2為一誘導酶,其功能為活化巨噬細胞或其他細胞,並充斥於炎症組織。 Specific cytokines activate their own cyclooxygenase (COX), which includes two major categories, COX-1 and COX-2. COX converts arachidonic acid into a large number of prostaglandins such as PGE 2 and PGF 2α. Recent research has found that Most normal tissues have not found the presence of COX-2, but it is indeed detectable in a variety of cancer patients, indicating the importance of COX-2 in cancer patients. In addition, COX-2 is an inducible enzyme whose function is to activate macrophages or other cells and to be filled with inflammatory tissues.

發炎部位產生熱感,主因為血管擴張素或組織胺被釋放,使得血管擴張及血液流量增加所造成。有些細胞會釋放出IL-17(Interleukin-1 alpha)的炎性細胞因子,或舊稱白細胞介素(Inflammatory cytokines)等物質;用以活化特定白血球白三烯來抵擋致敏原;其中細胞因子還包括趨化因子,該趨化因子會啟動細胞趨化機制以及干擾素,中止宿主細胞進行蛋白質的合成。而生長因子與細胞毒性分子也可能被釋出,進行組織的療癒。上述物質分泌時會使周圍細胞也受到影響,導致細胞間基質流失進而老化。 The inflammatory site produces a thermal sensation, mainly due to the release of vasodilators or histamine, resulting in vasodilation and increased blood flow. Some cells release IL-17 (Interleukin-1 alpha) inflammatory cytokines, or formerly known as interleukin cytokines; to activate specific white blood leukotrienes to resist allergens; Also included are chemokines that initiate cellular chemotaxis mechanisms and interferons that halt host cells for protein synthesis. Growth factors and cytotoxic molecules may also be released for tissue healing. When the above substances are secreted, the surrounding cells are also affected, resulting in loss of intercellular matrix and aging.

由上述四點老化成因可得知皮膚老化過程中,因表皮層角質細胞及真皮層纖維母細胞的增生減緩,造成皮膚內真皮層細胞外基質的大分子成分及結構性蛋白發生改變,而導致皮膚的皺褶、皮膚變薄、膚色黯淡、皮膚彈性降低及保濕度降低等老化現象。而紫外線則會誘導皮膚間質蛋白酶生成,該蛋白酶會分解皮膚膠原蛋白及彈性纖維蛋白組織,且紫外線亦會造成細胞內自由基濃度提高,進而導致皮膚產生發炎反應並提前進行老化;另,經紫外線照射過後,皮膚會產生活性氧化物質使細胞膜、結構蛋白、核酸等細胞結構遭到破壞,最終導致皮膚細胞癌化、死亡,並使皮膚基質流失造成外表皺紋累積。 It can be seen from the above four aging causes that the proliferation of epidermal keratinocytes and dermal fibroblasts is slowed down during skin aging, resulting in changes in the macromolecular components and structural proteins of the extracellular matrix in the dermis of the skin. Aging phenomenon such as wrinkles of the skin, thinning of the skin, dull skin, reduced skin elasticity, and reduced moisturization. Ultraviolet light induces the formation of skin interstitial protease, which decomposes skin collagen and elastin tissue, and ultraviolet light also causes an increase in the concentration of free radicals in the cells, which in turn causes the skin to produce an inflammatory reaction and premature aging; After ultraviolet radiation, the skin will produce active oxidizing substances to destroy the cell structure, structural proteins, nucleic acids and other cellular structures, eventually leading to canceration and death of skin cells, and the loss of skin matrix caused by the accumulation of skin wrinkles.

2.人類抗老化蛋白2. Human anti-aging protein

有研究指出,細胞受到紅酒中的化學物質白藜蘆醇(resveratrol)或熱量限制的刺激時,會啟動sirtuins family使其細胞週期延長。而Sinclair及其MIT Leonard Guarente實驗室發現,酵母菌中一種特殊的Sirtuins蛋白是以二種特定方式影響老化過程,Sirtuins可協助調控細胞中的基因活性並修補DNA中的斷裂。 Studies have shown that when cells are stimulated by resveratrol, a chemical in red wine, or calorie restriction, the sirtuins family is activated to prolong the cell cycle. Sinclair and its MIT Leonard Guarente laboratory found that a special Sirtuins protein in yeast affects the aging process in two specific ways. Sirtuins can help regulate gene activity in cells and repair DNA breaks.

Philipp Oberdoerffer,Sinclair實驗室,則利用微陣列平台於老鼠細胞中探測酵母菌sirtuin基因並尋找哺乳類動物之sirtuin基因序列;而老鼠研究結果亦證實了在脊椎動物上也有類似於酵母菌中之sirtuin基因。Oberdoerffer則發現,Sirtuin在哺乳類動物系統中的主要功能之一 是監督基因表現的模式;所有基因都會出現在所有細胞中,但於特定時間裡,只有少數幾個基因需要活化,若錯誤基因被活化則會導致細胞損傷進而使其進入細胞凋亡。 Philipp Oberdoerffer, Sinclair Laboratories, used the microarray platform to probe the yeast sirtuin gene in mouse cells and searched for the sirtuin gene sequence in mammals. The mouse study also confirmed that there is a sirtuin gene similar to yeast in vertebrates. . Oberdoerffer found that one of the main functions of Sirtuin in the mammalian system is to monitor the pattern of gene expression; all genes are present in all cells, but at a given time, only a few genes need to be activated, if the wrong gene is activated It can cause cell damage and cause it to enter apoptosis.

Sirtuins會將被抑制表現的基因去乙醯化,使其不受到環境因子破壞,並使受抑制基因維持其關閉狀態,保持細胞基因穩定;Sirtuins可協助保存染色質(chromatin),將基因與組蛋白(histone)共同收縮及包覆,並使其保持閒置狀態;當DNA因紫外光或自由基而受損時,Sirtuins會於受損處協助DNA修補機制;Sirtuins其保護功能可在基因造成永久性傷害前,將基因與蛋白包覆住以達到保護的效果。若未受Sirtuins保護,組蛋白會開始成鬆散狀,被保存抑制的基因則會重新被啟動,而使基因容易受外界干擾而損傷。 Sirtuins deacetylates genes that are inhibited from being destroyed by environmental factors, and keeps the suppressed genes in their off state, keeping the cells genetically stable; Sirtuins can help preserve chromatin, genes and groups. The protein (histone) shrinks and coats together and keeps it idle; when the DNA is damaged by ultraviolet light or free radicals, Sirtuins will assist the DNA repair mechanism in the damaged area; Sirtuins' protective function can cause permanent damage in the gene. Before sexual injury, the gene and protein are coated to achieve the protective effect. If it is not protected by Sirtuins, the histones will begin to become loose, and the genes that are preserved and suppressed will be reactivated, making the genes vulnerable to external disturbances.

當小鼠老化時,DNA受損速率會增加,此種損害會使基因表現失去管制,染色質不受其控制旋開,此時Sirtuins則會幫助控管全基因組的失控;而在此失控中被活化的基因,有許多是直接與老化顯型有直接關連的基因。 When the mouse ages, the rate of DNA damage increases. This damage causes the gene expression to be out of control. The chromatin is not controlled by its control. At this time, Sirtuins will help control the loss of control of the whole genome. Many of the genes that are activated are genes that are directly related to the aging phenotype.

其他研究則發現,未受Sirtuins控管失控之小鼠基因,會持續不斷地在老化的小鼠中出現。Oberdoerffer利用一隻經過基因改造的淋巴瘤小鼠動物模型,當給予小鼠額外的sirtuin基因拷貝,或餵食小鼠sirtuin活化劑(activator)--白藜蘆醇時,發現小鼠的平均壽命會被延長24%~46%。 Other studies have found that mouse genes that are not controlled by Sirtuins are continuously present in aging mice. Oberdoerffer uses a genetically engineered mouse model of lymphoma to give mice an extra copy of the sirtuin gene, or to feed the mouse sirtuin activator, resveratrol, to find the average lifespan of the mouse. It is extended by 24% to 46%.

Leonard Guarente的研究則指出,透過新藥物的使用,隨著時間穩定Sirtuins的重新分配,將會有新的方式來保護細胞避免老化。根據這種特定的機制,雖然DNA損傷會使老化惡化,但起因並非DNA受損本身,而是基因缺乏調控所致;Oberdoerffer研究亦指出,此調控基因活性的過程,稱為外遺傳(Epigenetics,表遺傳),不同於DNA中的實質突變;而透過對此原理的驗證,發現能夠以刺激Sirtuins的方式逆轉老化。 Leonard Guarente's research points out that through the use of new drugs, Stirtuins' redistribution will stabilize over time, and there will be new ways to protect cells from aging. According to this particular mechanism, although DNA damage can worsen aging, the cause is not DNA damage itself, but the lack of regulation of genes; the Oberdoerffer study also pointed out that this process of regulating gene activity is called epigenetics (Epigenetics, Epigenetic), unlike the substantial mutations in DNA; and by verifying this principle, it was found that aging can be reversed in a way that stimulates Sirtuins.

3. 皮膚穿透加強劑(Transdermal Penetration Enhancers,TPE)3. Transdermal Penetration Enhancers (TPE)

新藥研究需耗費很多金錢及時間,故給藥系統之開發,越來越受重視。 最常見的藥物服用方式,包括口服給藥、皮下組織注射給藥及經皮給藥。口服給藥是一種最常用的給藥方式,藥物在經口服後,通過胃腸粘膜吸收進入血液,達到局部或全身的治療作用。而口服給藥的缺點在於:藥物經體內吸收慢而不規則,使得藥物無法達到治療作用;再者藥物到達血液前要先經過肝臟,使得藥物之藥效受到破壞,也對肝臟造成負擔;有些藥物則因腸內無法吸收或具有刺激性而不能口服;而口服給藥的最大缺點,在於藥物會在體內造成副作用,使得病患會有噁心、嘔吐等身體上的不適應。另一種給藥方式為皮下組織注射法,該方法是將藥物直接注入皮下,經皮下微血管吸收而輸送到全身,其優點在於藥物不會受到胃液和肝臟影響,可以直接進入血管並流經身體各個部位,達到治療目的;皮下組織注射法與口服法相比,大大的提升了給藥的速率,但對於長期依賴注射給藥的病人來說,卻需要長期承受因注射所造成的疼痛負擔。又另一種給藥方式為經皮給藥系統(Transdermal Drug Delivery system,TDDS),於該系統中藥物是通過皮膚來吸收的;給藥後,藥物會在預定時間內,穿過皮膚角質層,並經微血管滲透吸收後,進入血液循環而產生作用,進而達到全身治療的目的(Saunders et al.,1999)。 New drug research takes a lot of money and time, so the development of drug delivery systems is getting more and more attention. The most common modes of administration of drugs include oral administration, subcutaneous tissue injection, and transdermal administration. Oral administration is one of the most commonly used modes of administration. After oral administration, the drug is absorbed into the blood through the gastrointestinal mucosa to achieve a local or systemic therapeutic effect. The disadvantage of oral administration is that the absorption of the drug through the body is slow and irregular, so that the drug can not achieve the therapeutic effect; in addition, the drug must pass through the liver before reaching the blood, so that the drug effect is destroyed, and the burden on the liver is also caused; The drug cannot be taken orally because it cannot be absorbed or irritated in the intestine; the biggest disadvantage of oral administration is that the drug causes side effects in the body, and the patient may have physical discomfort such as nausea and vomiting. Another method of administration is subcutaneous tissue injection, which directly injects the drug into the skin and is transported to the whole body through subcutaneous microvascular absorption. The advantage is that the drug is not affected by gastric juice and liver, and can directly enter the blood vessel and flow through the body. The site is used for therapeutic purposes; the subcutaneous tissue injection method greatly increases the rate of administration compared with the oral method, but for patients who have long-term dependence on injection, it is necessary to bear the pain burden caused by the injection for a long time. Yet another mode of administration is the Transdermal Drug Delivery System (TDDS), in which the drug is absorbed through the skin; after administration, the drug passes through the stratum corneum of the skin within a predetermined time. After microvascular osmotic absorption, it enters the blood circulation and acts to achieve systemic therapy (Saunders et al., 1999).

經皮給藥治療系統具有的優點包括:生產容易、成本低廉、可以恆定速率進入體內、可於血液中長時間維持穩定的濃度、減少給藥頻率、低毒副作用、避免肝臟的首渡效應、降低藥物代謝、減少用藥的個體差異、提高生體可用率及小劑量即可達到治療的效果等優點。另,經皮給藥適用於年幼、老人或不易服藥之病患;用藥方便,發生問題時能立即移除,停止給藥。由於經皮給藥具有上述之優點,此系統備受矚目;目前經皮給藥的開發研究,已從局部向全身、靶向器官及控釋機制發展,並已應用在臨床上(Shin et al.,2005)。 The advantages of the transdermal drug delivery system include: easy production, low cost, a constant rate of entry into the body, stable concentration in the blood for a long time, reduced frequency of administration, low toxicity, and avoidance of the liver's first-pass effect, Reduce drug metabolism, reduce individual differences in medication, increase the availability of organisms and small doses to achieve therapeutic effects. In addition, transdermal administration is suitable for young, elderly or patients who are not easy to take the medicine; it is convenient to use, and can be removed immediately when the problem occurs, and the administration is stopped. Due to the above advantages of transdermal administration, this system has attracted much attention; currently research and development of transdermal drug delivery has been developed from local to systemic, targeted organs and controlled release mechanisms, and has been applied clinically (Shin et al ., 2005).

經皮給藥系統最大的障礙就是皮膚的角質層,角質層(stratum corneum,SC)是皮膚的最上層,由扁平長型的角質細胞組成,角質細胞的四周則環繞著層狀的脂肪(Norlen,2001);角質層最主要的功能為阻止外界物質進入體內、防止體內水分散失,為皮膚最外層的屏障(Bouwstra et al.,2003)。1973年學者Breathnach等人利用電子顯微鏡發現角質層細胞 間隙充滿了脂肪,開始認為角質層脂肪在皮膚障壁功能上扮演重要的地位(Breathnach et al.,1973)。亦有研究指出,當角質層溫度上升時,角質層細胞間脂肪的流動性增加,皮膚經皮吸收滲透性也隨之增加(Golden et al.,1987);若將角質層中的脂質去除後,則可明顯增加親水性及兩性藥品對皮膚的滲透性,但對親脂性的藥物不具顯著的影響(Tsai et al.,2001)。 The biggest obstacle to the transdermal drug delivery system is the stratum corneum of the skin. The stratum corneum (SC) is the uppermost layer of the skin. It consists of flat long keratinocytes surrounded by stratified fat (Norlen). , 2001); The most important function of the stratum corneum is to prevent foreign substances from entering the body and prevent the water from dispersing in the body, which is the outermost barrier of the skin (Bouwstra et al., 2003). In 1973, scholar Breathnach et al. used electron microscopy to find stratum corneum cells. The gap is full of fat and begins to assume that stratum corneum fat plays an important role in skin barrier function (Breathnach et al., 1973). Studies have also shown that when the temperature of the stratum corneum rises, the fluidity of intercellular fat in the stratum corneum increases, and the percutaneous absorption permeability of the skin also increases (Golden et al., 1987); if the lipid in the stratum corneum is removed It can significantly increase the permeability of hydrophilic and amphoteric drugs to the skin, but has no significant effect on lipophilic drugs (Tsai et al., 2001).

克服經皮吸收的障礙問題,可使用下列三種方法:第一種是物理方法,給予一個外來的能量,使皮膚造成短暫性的孔洞,促進藥物吸收;常見的處理方式有超音波(ultrasound)、電離子透入(iontophoresis)、微型針頭列陣(microneedle array)及熱能量(thermal energy)。第二種則為生化方法,利用合成生物轉化前驅物以及和新陳代謝之抑制劑共同投藥,以增加藥物之吸收。第三種為化學方法,使用微脂粒(liposome)包覆藥物或添加皮膚穿透加強劑(penetration enhancer),微脂粒是由彎曲的雙層脂質組成,形成親水朝外疏水端在內之雙面親水夾層,可同時作為油性與水性物質的載體,油性藥物可嵌入脂質雙層中,而水性藥物則可包覆在微脂粒的水相中;微脂粒與細胞作用的機制有四種,第一種為膜組成交換(intermembrane transfer),即微脂粒膜的組成與細胞膜的組成中有一部份互相交換;第二種是吸著(adsorption),微脂粒附著於細胞膜;第三種方式是膜融合(fusion),微脂粒與細胞膜融合,將包容物送進細胞內;最後一種是吞食(phagocytosis,endocytosis),微脂粒被細胞吞食。而皮膚穿透加強劑(penetration enhancer)是指可加速藥物穿透皮膚的速度及含量,但不會對皮膚造成嚴重刺激及傷害的物質(Williams and Barry,1991);皮膚穿透加強劑主要是作用在角質層的脂質層(intercelluar),擾亂其規則結構及提高其流動性,並且作用在角蛋白(keratin)上,鬆弛角細胞結構,增加藥物在角質層中的溶解度,達到增加藥物吸收的目的(Walker and Smith,1996)。添加皮膚穿透加強劑是相當具有發展潛力的助滲方法(Saunders et al.,1999)。 To overcome the problem of percutaneous absorption, the following three methods can be used: The first is a physical method that gives an external energy to cause transient pores in the skin and promote drug absorption; common treatments include ultrasound, Iontophoresis, microneedle array, and thermal energy. The second is a biochemical method that uses synthetic biotransformation precursors and inhibitors with metabolic agents to increase drug absorption. The third is a chemical method in which a drug is coated with a liposome or a skin enhancer is added. The liposome is composed of a curved double-layered lipid, forming a hydrophilic outward-facing hydrophobic end. Double-sided hydrophilic interlayer can be used as a carrier for oily and aqueous substances at the same time. Oily drugs can be embedded in the lipid bilayer, while aqueous drugs can be coated in the aqueous phase of the liposome. The mechanism of action of the microlipids and cells is four. The first type is intermembrane transfer, that is, the composition of the liposome membrane is exchanged with a part of the composition of the cell membrane; the second is adsorption, and the liposome is attached to the cell membrane; The three methods are membrane fusion, the liposome is fused with the cell membrane, and the inclusion is sent into the cell; the last one is phagocytosis (endocytosis), and the liposome is swallowed by the cells. A skin penetration enhancer is a substance that accelerates the rate and content of a drug that penetrates the skin, but does not cause serious irritation and damage to the skin (Williams and Barry, 1991); the skin penetration enhancer is mainly It acts on the interstitial layer of the stratum corneum, disturbs its regular structure and improves its fluidity, and acts on keratin, relaxes the angular cell structure, increases the solubility of the drug in the stratum corneum, and increases the absorption of the drug. Purpose (Walker and Smith, 1996). The addition of skin penetration enhancers is a relatively promising method of infiltration (Saunders et al., 1999).

界面活性劑是一種良好的皮膚穿透加強劑,對生物膜及皮膚都有協助滲透的效果(Lopez et al.,2000),近年來已經廣泛的應用於藥物穿透(Nokhodchi et al.,2003;Shokri et al.,2001)。2001年Nokhodchi等人的研究指出,界面活性劑烷基硫酸鹽(sodium lauryl sulfate,SLS)、溴化十六烷三 甲基銨(cetyltrimethylammonium bromide,CTAB)及氯化苯二甲烴銨(Benzalkonium Chloride)可促進小鼠皮膚對抗憂鬱藥物Diazepam的吸收(Shokri et al.,2001)。Nokhodchi等人對另一個關於抗憂鬱藥物的研究指出,界面活性劑烷基硫酸鹽(sodium lauryl sulfate,SLS)、溴化十六烷三甲基銨(cetyltrimethylammonium bromide,CTAB)及氯化苯二甲烴銨(Benzalkonium Chloride)可促進小鼠皮膚對抗憂鬱藥物lorazepam的吸收(Nokhodchi et al.,2003)。而表面素對人工合成的細胞膜、原生生物的細胞膜及真核生物的細胞膜具有相當好的親和力(Maget-Dana and Ptak,1995;Sheppard et al.,1991;Tsukagoshi et al.,1970b);且表面素對和細胞膜的結合是具有高度選擇性的,這是因為表面素對於膽固醇(cholesterol)及磷脂質(phospholipid)的親和力很高,而細胞膜的結構就是以這兩個物質為主(Hosono and Suzuki,1985)。若和化學合成的界面活性劑相比,表面素較溫和,不會對皮膚造成傷害。 Surfactant is a good skin penetration enhancer that aids in the penetration of biofilms and skin (Lopez et al., 2000) and has been widely used in drug penetration in recent years (Nokhodchi et al., 2003). Shokri et al., 2001). In 2001, Nokhodchi et al. pointed out that the surfactant lasulfate sulfate (SLS), cetyl bromide Cetyltrimethylammonium bromide (CTAB) and Benzalkonium Chloride promote the absorption of the skin of the mouse against the depressive drug Diazepam (Shokri et al., 2001). Nokhodchi et al. pointed out another study on antidepressant drugs, such as sodium lauryl sulfate (SLS), cetyltrimethylammonium bromide (CTAB) and chlorinated phthalate. Benzalkonium Chloride promotes the absorption of the mouse skin against the depressive drug lorazepam (Nokhodchi et al., 2003). Surface elements have a fairly good affinity for synthetic cell membranes, cell membranes of protists, and cell membranes of eukaryotes (Maget-Dana and Ptak, 1995; Sheppard et al., 1991; Tsukagoshi et al., 1970b); The binding of the element to the cell membrane is highly selective because the affinity of the surface element for cholesterol (cholesterol) and phospholipid is high, and the structure of the cell membrane is dominated by these two substances (Hosono and Suzuki). , 1985). If it is milder than chemically synthesized surfactants, it will not cause damage to the skin.

一般傳統的方法,藥物或營養活性物質只能滲透入表皮的阻隔層(即角質層),效果並不顯著(只達到約百分之零點三的成效);為解決這個問題,有很多經皮吸收技術被研發出來,目的是有效提升養分的滲透能力,使養份穿越皮膚表皮層及真皮層細胞,因此養分輸送方法變成為護膚科技的研究重點之一。 In the conventional method, the drug or nutrient active substance can only penetrate into the barrier layer of the epidermis (ie, the stratum corneum), and the effect is not significant (only about 0.3% of the effect); to solve this problem, there are many The skin absorption technology has been developed with the aim of effectively improving the penetration of nutrients and allowing nutrients to pass through the epidermal and dermal cells of the skin. Therefore, the nutrient delivery method has become one of the research priorities of skin care technology.

雖然人類皮膚的角質層很薄,其厚度僅為10-25微米,最薄的角質層在上眼皮,僅有6微米厚,但卻相當“堅韌”,是皮膚最重要的保護層。而一般化妝品原料經皮滲入主要是經過3種途徑:1.經汗腺管(sweat duct);2.直接穿過角質層(stratum corneum);及3.經過毛囊(hair follicle)。 Although the stratum corneum of human skin is very thin, its thickness is only 10-25 microns. The thinnest stratum corneum is only 6 microns thick in the upper eyelid, but it is quite "tough" and is the most important protective layer of skin. The general cosmetic raw materials percutaneously infiltrated mainly through three ways: 1. through the sweat duct; 2. directly through the stratum corneum (stratum corneum); and 3. through the hair follicle (hair follicle).

化妝品原料以黃金為例,現代黃金美容研究證實,黃金具有解毒、鎖靜、潔淨及去皺的功能,使用後可使肌膚重組細胞因數,促進生理機能、新陳代謝、平衡油脂分泌及保持天然水分,並可抵抗外界引起的過敏。而化妝品原料中常用的奈米金,其大小相當於人類毛細孔的200分之一,因此使用含奈米純金微粒護膚品塗於肌膚時,是希望奈米金能效瞬間深入真皮層細胞。 Cosmetics raw materials take gold as an example. Modern gold beauty research has confirmed that gold has the functions of detoxification, lock, cleansing and wrinkle removal. After use, it can reconstitute cytokines of skin, promote physiological functions, metabolism, balance oil secretion and maintain natural moisture. It can also resist allergies caused by the outside world. Nano-gold, which is commonly used in cosmetic raw materials, is about one-twentieth the size of human hair pores. Therefore, when using nano-pure skin care products applied to the skin, it is hoped that nano-gold energy will penetrate into the dermis cells instantaneously.

當奈米金進入真皮層後,奈米金可在基因的層次上,調節真皮細胞功能,其中包括促進真皮細胞產生一系列活性物質,包括SOD、金屬硫蛋白、EGF等。由於SOD可清除羥基自由基,金屬硫蛋白又能抵抗皮層細胞受紫外線的損傷,所以奈米金對真皮細胞具有抗衰老的效果。亦有其他研究顯示奈米金能刺激纖維細胞,進而分泌合成新的胞外基質(ECM),刺激纖維母細胞分泌膠原蛋白,和刺激纖維細胞呈現及分泌表皮生長因子(EGF),來分化目標細胞特異的角化細胞生長因子(KGF);同時也就加強了皮膚的緊致度,讓皮膚平滑而充滿彈力,發出閃亮的光輝。 When nanogold enters the dermis, nanogold regulates dermal cell function at the gene level, including the promotion of dermal cells to produce a range of active substances, including SOD, metallothionein, and EGF. Since SOD can scavenge hydroxyl radicals, and metallothionein can resist the damage of cortical cells by ultraviolet rays, nanogold has an anti-aging effect on dermal cells. Other studies have shown that nanogold can stimulate fiber cells, secrete new synthetic extracellular matrix (ECM), stimulate fibroblasts to secrete collagen, and stimulate fiber cells to present and secrete epidermal growth factor (EGF) to differentiate targets. Cell-specific keratinocyte growth factor (KGF); at the same time, it strengthens the skin's firmness, leaving the skin smooth and elastic, giving off a sparkling glow.

4.生物乳化劑(Bioemulsifier)4. Bioemulsifier

表面素除了可作為抗菌肽之外,表面素更扮演了另外一個重要的角色,生物乳化劑(bioemulsifier)。1999年Deleu等人發現在抑制乳析及絮凝作用的測試中,伊枯草桿菌素的效果會較表面素好,在對烷類的乳化效果測試中,表面素對烷類的乳化效果,遠大於伊枯草桿菌素及豐原素,乳化效果最差的是化學合成的陰離子界面活性劑十二烷基硫酸鈉(Sodium dodecyl sulfate,SDS)。其他研究顯示,添加20mg/l的表面素可增加柴油生物分解性,且更進一步指出pH值會影響表面素對柴油的乳化效力,將pH值調整為7.4時,表面素對柴油的生物分解性最佳。 In addition to being used as an antimicrobial peptide, surface keratin plays another important role as a bioemulsifier. In 1999, Deleu et al found that in the test for inhibiting lactation and flocculation, the effect of italin was better than that of surface. In the test of the emulsifying effect on alkanes, the emulsifying effect of surface elements on alkanes was much greater than that. The most emulsified effect of the herbicidal and abundance is the chemically synthesized anionic surfactant Sodium dodecyl sulfate (SDS). Other studies have shown that the addition of 20mg / l of surface hormone can increase the biodegradability of diesel, and further pointed out that the pH value will affect the emulsifying efficiency of surface oil to diesel, the biodegradability of surface oil to diesel when the pH is adjusted to 7.4. optimal.

5. 起泡劑5. Foaming agent

除了一般界面活性劑具有之乳化能力外,表面素亦具有起泡能力(Razafindralambo et al.,1998)。所謂起泡現象是指,表面素會存在於氣相及液相的界面中,劇烈搖晃使界面活性劑將空氣抓下,形成內含空氣的薄膜(Halling,1981)。Razafindralambo等人亦指出,和伊枯草菌素相比,表面素具有較優異的起泡效果,推測是和兩者之間的結構有關係,表面素屬於陰離子界面活性劑,其脂肪酸碳鏈較短,而伊枯草桿菌素則為非離子界面活性劑,脂肪酸碳鏈較長(Razafindralambo,et al.,1998)。 In addition to the emulsifying ability of general surfactants, surface elements also have foaming ability (Razafindralambo et al., 1998). The so-called foaming phenomenon means that surface elements are present in the interface between the gas phase and the liquid phase, and the shaking is vigorously caused to cause the surfactant to catch the air to form a film containing air (Halling, 1981). Razafindralambo et al. also pointed out that surface priming has superior foaming effect compared with italin, presumably related to the structure between the two, surface element is an anionic surfactant, and its fatty acid carbon chain is shorter. While imipenem is a nonionic surfactant with a long fatty acid carbon chain (Razafindralambo, et al., 1998).

本發明之目的在提供一種以表面素(surfactin)製備抗老化(或抗皺紋)化妝品組合物的方法,其中該組合物係包含表面素及藥學上可接受之載劑、賦形劑、稀釋劑、輔劑等;其中該表面素為一環脂胜肽分子, 由7個胺基酸組成(L-Aspartic acid,L-leucine,glutamic acid,L-leucine,L-valine與兩個D-leucines)之環狀7肽(heptapeptide)結構。此環化7肽連接一個β-羥基脂肪酸,其中又以異14烷(isoC14)羥基為主(17%~35%);其中該表面素在脂肪酸末端之脂肪酸分布如下:(1)異C13大於3%;(2)正C13大於0.65%;(3)異C14大於17%;(4)正C14少於41%;及(5)異C15少於11%;其中該脂肪酸末端之脂肪酸分布以下列分布為較佳:(1)異C13大於10%;(2)正C13大於25%;(3)異C14大於35%;(4)正C14少於25%;及(5)異C15少於3%;其中該脂肪酸末端之脂肪酸分布以下列分布為最佳:(1)異C 13為11%;(2)正C13為26%;(3)異C 14為37%;(4)正C14為24%;及(5)異C15為2%;其中該表面素之分子量為1022或1036Da;其中該表面素包含其化學異構物。(參見中華民國專利申請號097137532)。 It is an object of the present invention to provide a method of preparing an anti-aging (or anti-wrinkle) cosmetic composition using surfactin, wherein the composition comprises a surface element and a pharmaceutically acceptable carrier, excipient, diluent , an adjuvant, etc.; wherein the surface element is a cyclolipopeptide molecule, A cyclic heptapeptide structure consisting of 7 amino acids (L-Aspartic acid, L-leucine, glutamic acid, L-leucine, L-valine and two D-leucines). The cyclized 7 peptide is linked to a β-hydroxy fatty acid, which is dominated by an iso14 (isoC14) hydroxyl group (17% to 35%); wherein the fatty acid distribution of the surface element at the fatty acid terminal is as follows: (1) the iso C13 is greater than 3%; (2) positive C13 is greater than 0.65%; (3) iso-C14 is greater than 17%; (4) positive C14 is less than 41%; and (5) iso-C15 is less than 11%; wherein the fatty acid terminal fatty acid distribution is below The column distribution is preferably: (1) different C13 is greater than 10%; (2) positive C13 is greater than 25%; (3) iso C14 is greater than 35%; (4) positive C14 is less than 25%; and (5) less than C15 is less 3%; wherein the fatty acid distribution at the terminal of the fatty acid is optimal in the following distributions: (1) 11% for the iso C 13; (2) 26% for the positive C13; (3) 37% for the different C 14; (4) Positive C14 is 24%; and (5) iso C15 is 2%; wherein the surface element has a molecular weight of 1022 or 1036 Da; wherein the surface element comprises its chemical isomer. (See Republic of China Patent Application No. 097137532).

其中該抗老化(或抗皺紋)化妝品組合物可進一步包含下列至少一者:醇類、酯類、複合多醣體、堅果油及維生素;其中該醇類係包括下列至少一者:C16-18醇、丁二醇、戊二醇、辛二醇、丙三醇、16醇、18醇、22醇及丙二醇;其中該酯類係包括下列至少一者:橄欖油鯨蠟醇酯(OLIVEM 1000)、單硬脂酸甘油酯(GSM)、十四酸異丙酯(IPM)、十六酸異丙酯(IPP)及三酸甘油酯;其中該複合多醣體係包括下列至少一者:漢生膠、銀耳多醣體、葡聚多醣體、狹葉番瀉籽多醣體;其中該堅果油係包括下列至少一者:阿甘油、夏威夷核果油、酪梨油、小麥胚芽油、橄欖油;其中該維生素係包括下列至少一者:維生素A、維生素B、維生素C、維生素E、維生素F、維生素K。 Wherein the anti-aging (or anti-wrinkle) cosmetic composition may further comprise at least one of the following: an alcohol, an ester, a complex polysaccharide, a nut oil, and a vitamin; wherein the alcohol comprises at least one of the following: C16-18 alcohol Butanediol, pentanediol, octanediol, glycerol, 16 alcohol, 18 alcohol, 22 alcohol and propylene glycol; wherein the ester comprises at least one of the following: olive oil cetyl alcohol ester (OLIVEM 1000), Glyceryl monostearate (GSM), isopropyl myristate (IPM), isopropyl palmitate (IPP) and triglyceride; wherein the composite polysaccharide system comprises at least one of the following: xanthan gum, white fungus a polysaccharide body, a glucoside polysaccharide, a senna seed polysaccharide; wherein the nut oil comprises at least one of the following: argan oil, Hawaiian stone oil, avocado oil, wheat germ oil, olive oil; wherein the vitamin system comprises At least one of the following: vitamin A, vitamin B, vitamin C, vitamin E, vitamin F, vitamin K.

其中該抗老化(或抗皺紋)化妝品組合物係用以促進纖維母細胞之增殖、抗紫外光老化、抗氧化、促進sertuin 1基因的表現、促進膠原蛋白的增生和抑制基質金屬蛋白酶(Matrix metallopeptidase);其中該基質金屬蛋白酶為基質金屬蛋白酶九型(Matrix metallopeptidase 9)。 The anti-aging (or anti-wrinkle) cosmetic composition is used for promoting the proliferation of fibroblasts, anti-UV aging, anti-oxidation, promoting the expression of sertuin 1 gene, promoting collagen proliferation and inhibiting matrix metalloproteinase (Matrix metallopeptidase). Wherein the matrix metalloproteinase is Matrix metallopeptidase 9 (Matrix metallopeptidase 9).

本發明進一步提供一種以表面素(surfactin)製備增加皮膚穿透力之組合物的方法,其中該組合物係包含表面素及藥學上可接受之載劑、賦形劑、稀釋劑、輔劑等;其中該表面素為一種環脂胜肽,該表面素 包括連接至β羥基脂肪酸之七胜肽序(L)Glu-(L)Leu-(D)Leu-(L)Val-(L)Asp-(D)Leu-(L)Leu,該表面素在脂肪酸末端之脂肪酸分布如下:(1)異C13大於3%;(2)正C13大於0.65%;(3)異C14大於17%;(4)正C14少於41%;及(5)異C15少於11%;其中該脂肪酸末端之脂肪酸分布以下列分布為較佳:(1)異C13大於10%;(2)正C13大於25%;(3)異C14大於35%;(4)正C14少於25%;及(5)異C15少於3%;其中該脂肪酸末端之脂肪酸分布以下列分布為最佳:(1)異C 13為11%;(2)正C13為26%;(3)異C 14為37%;(4)正C14為24%;及(5)異C15為2%;其中該表面素之分子量為1022或1036Da;其中該表面素包含其化學異構物;其中該增加皮膚穿透力之組合物可進一步包含下列至少一者:醇類、酯類、複合多醣體、堅果油及維生素;其中該醇類係包括下列至少一者:C16-18醇、丁二醇、戊二醇、辛二醇、丙三醇、16醇、18醇、22醇及丙二醇;其中該酯類係包括下列至少一者:橄欖油鯨蠟醇酯(OLIVEM 1000)、單硬脂酸甘油酯(GSM)、十四酸異丙酯(IPM)、十六酸異丙酯(IPP)及三酸甘油酯;其中該複合多醣體係包括下列至少一者:漢生膠、銀耳多醣體、葡聚多醣體、狹葉番瀉籽多醣體;其中該堅果油係包括下列至少一者:阿甘油、夏威夷核果油、酪梨油、小麥胚芽油、橄欖油;其中該維生素係包括下列至少一者:維生素A、維生素B、維生素C、維生素E、維生素F、維生素K。。 The present invention further provides a method of preparing a composition for increasing skin penetration by surfactin, wherein the composition comprises a surface element and a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, etc. Wherein the surface element is a cyclolipin peptide, the surface element Including a seven-peptide sequence (L) Glu-(L)Leu-(D)Leu-(L)Val-(L)Asp-(D)Leu-(L)Leu linked to a beta hydroxy fatty acid, the surface element is The fatty acid distribution at the fatty acid terminal is as follows: (1) the iso C13 is greater than 3%; (2) the positive C13 is greater than 0.65%; (3) the iso C14 is greater than 17%; (4) the positive C14 is less than 41%; and (5) the iso C15 Less than 11%; wherein the fatty acid distribution at the end of the fatty acid is preferably the following distribution: (1) different C13 is greater than 10%; (2) positive C13 is greater than 25%; (3) iso-C14 is greater than 35%; (4) positive C14 is less than 25%; and (5) iso C15 is less than 3%; wherein the fatty acid distribution at the terminal of the fatty acid is optimal in the following distributions: (1) 11% of iso C 13; (2) 26% of positive C13; (3) the specific C 14 is 37%; (4) the positive C14 is 24%; and (5) the iso C15 is 2%; wherein the surface element has a molecular weight of 1022 or 1036 Da; wherein the surface element comprises its chemical isomer The composition for increasing skin penetration may further comprise at least one of the following: an alcohol, an ester, a complex polysaccharide, a nut oil, and a vitamin; wherein the alcohol comprises at least one of the following: C16-18 alcohol, Butanediol, pentanediol, octanediol, glycerol, 16 alcohol, 18 alcohol, 22 alcohol and propylene glycol; wherein the ester is packaged Including at least one of the following: olive oil cetyl alcohol ester (OLIVEM 1000), glyceryl monostearate (GSM), isopropyl myristate (IPM), isopropyl palmitate (IPP) and triglyceride The complex polysaccharide system comprises at least one of the following: xanthan gum, tremella polysaccharide, glucoside polysaccharide, senna seed polysaccharide; wherein the nut oil comprises at least one of the following: argan oil, Hawaiian stone oil , avocado oil, wheat germ oil, olive oil; wherein the vitamin includes at least one of the following: vitamin A, vitamin B, vitamin C, vitamin E, vitamin F, vitamin K. .

其中該增加皮膚穿透力之組合物係用以促進化妝品原料穿透皮膚;其中該化妝品原料為皮質類固醇(dexamethasone)、玻尿酸(hyaluronic acid)、聚麩胺酸(Gamma-polyglutamic acid)和奈米金(gold-nanoparticles)。 The composition for increasing skin penetration is used to promote the penetration of cosmetic raw materials into the skin; wherein the cosmetic raw materials are dexamethasone, hyaluronic acid, gamma-polyglutamic acid and nanometer. Gold-nanoparticles.

本發明更提供一種以表面素(surfactin)製備乳化劑組合物的方法,其中該乳化劑組合物係包含表面素及藥學上可接受之載劑、賦形劑、稀釋劑、輔劑等;其中該表面素為一種環脂胜肽,該表面素包括連接至β羥基脂肪酸之七胜肽序(L)Glu-(L)Leu-(D)Leu-(L)Val-(L)Asp-(D)Leu-(L)Leu,該表面素在脂肪酸末端之脂肪酸分布如下:(1)異C13大於3%;(2)正C13大於0.65%;(3)異C14大於17%;(4)正C14少於41%;及(5)異C15少於11%;其中該脂肪酸末端之脂肪酸分布以下列分布為較佳:(1)異 C13大於10%;(2)正C13大於25%;(3)異C14大於35%;(4)正C14少於25%;及(5)異C15少於3%;其中該脂肪酸末端之脂肪酸分布以下列分布為最佳:(1)異C 13為11%;(2)正C13為26%;(3)異C 14為37%;(4)正C14為24%;及(5)異C15為2%;其中該表面素之分子量為1022或1036Da;其中該表面素包含其化學異構物;其中該乳化劑組合物可進一步包含下列至少一者:脂肪酸甘油酯、脂肪酸山梨醇酐酯、脂肪酸蔗糖酯、脂肪酸丙二醇酯、卵磷脂。 The present invention further provides a method for preparing an emulsifier composition by surfactant, wherein the emulsifier composition comprises a surface element and a pharmaceutically acceptable carrier, an excipient, a diluent, an adjuvant, etc.; The surface element is a cyclolipin peptide comprising a seven-peptide sequence (L) Glu-(L)Leu-(D)Leu-(L)Val-(L)Asp- linked to a beta hydroxy fatty acid. D) Leu-(L)Leu, the fatty acid distribution of the surface element at the fatty acid end is as follows: (1) the iso-C13 is greater than 3%; (2) the positive C13 is greater than 0.65%; (3) the iso-C14 is greater than 17%; (4) Positive C14 is less than 41%; and (5) iso C15 is less than 11%; wherein the fatty acid distribution at the terminal of the fatty acid is preferably the following distribution: (1) different C13 is greater than 10%; (2) positive C13 is greater than 25%; (3) iso-C14 is greater than 35%; (4) positive C14 is less than 25%; and (5) iso-C15 is less than 3%; wherein the fatty acid terminal fatty acid The distribution is optimal with the following distributions: (1) iso C 13 is 11%; (2) positive C13 is 26%; (3) iso C 14 is 37%; (4) positive C14 is 24%; and (5) The iso-C15 is 2%; wherein the surface element has a molecular weight of 1022 or 1036 Da; wherein the surface element comprises a chemical isomer thereof; wherein the emulsifier composition further comprises at least one of the following: fatty acid glyceride, fatty acid sorbitan Ester, fatty acid sucrose ester, fatty acid propylene glycol ester, lecithin.

其中該乳化劑組合物係用以增加起泡力、增加乳化作用、增加滑順感;其中該乳化劑組合物係用以增加清潔用品的起泡力,該清潔用品係為洗髮精、洗面乳、洗手乳及沐浴精等;其中該乳化劑組合物係用以增加化妝品的乳化力,該化妝品係為身體乳、面霜、精華液、隔離霜等;其中該乳化劑組合物係用以增加清潔用品的滑順感,該清潔用品係為洗髮精、洗面乳、洗手乳及沐浴精等。 Wherein the emulsifier composition is used to increase foaming power, increase emulsification, and increase smoothness; wherein the emulsifier composition is used to increase the foaming power of the cleaning article, which is shampoo and facial cleansing. Milk, hand lotion, bath essence, etc.; wherein the emulsifier composition is used to increase the emulsifying power of the cosmetic, the body is a body lotion, a cream, an essence, a cream, etc.; wherein the emulsifier composition is used to increase The smoothness of the cleaning products, such as shampoo, facial cleanser, hand lotion and bath essence.

第1圖 不同濃度表面素對於小鼠胚胎纖維母細胞(BALB/3T3 clone A31 Mus musculus embryo fibroblast)之長壽基因(sertuin 1基因)mRNA表現的影響;將小鼠胚胎纖維母細胞培養於不同濃度的表面素(0、25、50、75、100μM),培養時間為6、12、24、36、48小時。 Figure 1 Effect of different concentrations of surface hormone on the expression of longevity gene ( sertuin 1 gene) in mouse embryonic fibroblasts (BALB/3T3 clone A31 Mus musculu s embryo fibroblast); culture of mouse embryonic fibroblasts at different concentrations Surface elements (0, 25, 50, 75, 100 μM), culture time was 6, 12, 24, 36, 48 hours.

第2圖 白藜蘆醇(Resveratrol)、五胜肽(Palmitoyl pentapeptide-3)及表面素對細胞增殖的影響;將小鼠胚胎纖維母細胞培養於不同濃度的表面素(0、25、50、75、100μM)、白藜蘆醇(0、5、10、20、30μM)和五胜肽(0、3、5、8、10μM),培養時間為48小時。 Figure 2 Effect of Resveratrol, Palmitoyl pentapeptide-3 and surface cytokines on cell proliferation; Mouse embryonic fibroblasts were cultured at different concentrations of surface proteins (0, 25, 50, 75, 100 μM), resveratrol (0, 5, 10, 20, 30 μM) and pentapeptide (0, 3, 5, 8, 10 μM), culture time was 48 hours.

第3圖 表面素抗光老化的作用;不同濃度之表面素對受過紫外光照射後之小鼠胚胎纖維母細胞之存活率的影響;細胞以5J/cm2、10J/cm2及15J/cm2之紫外光照射後,添加25、50、75、100及125μM濃度之表面素,培養24小時後,以MTT法測試細胞活存率。 Fig. 3 The effect of surface keratin on photoaging; the effect of different concentrations of surface elements on the survival rate of mouse embryonic fibroblasts after exposure to ultraviolet light; cells with UV of 5 J/cm2, 10 J/cm2 and 15 J/cm2 After light irradiation, surface concentrations of 25, 50, 75, 100, and 125 μM were added, and after 24 hours of culture, the cell survival rate was measured by the MTT method.

第4圖 表面素對小鼠胚胎纖維母細胞之抗氧化壓力的保護效果;細胞以 100、150、200及250μM濃度的過氧化氫處理後,再添加0、25、50、75及100μM濃度之表面素,培養24小時,然後以MTT法測試細胞存活率。 Figure 4 The protective effect of surface elements on the anti-oxidative stress of mouse embryonic fibroblasts; After treatment with hydrogen peroxide at concentrations of 100, 150, 200 and 250 μM, surface concentrations of 0, 25, 50, 75 and 100 μM were added and cultured for 24 hours, and then cell viability was tested by MTT assay.

第5圖 表面素與五胜肽對小鼠胚胎纖維母細胞之膠原蛋白含量(collagen dose)的影響;其中膠原蛋白含量是以Sircol collagen assay來測量;小鼠胚胎纖維母細胞是以不同濃度之表面素(0、25、50、75、100μM)和五胜肽(0、3、5、8、10μM)培養24小時;PBS:磷酸鹽緩衝溶液;a,b,ab,c,d代表若符號相同則沒有統計上之差異。 Figure 5: Effect of surface and pentapeptide on the collagen dose of mouse embryonic fibroblasts; collagen content is measured by Sircol collagen assay; mouse embryonic fibroblasts are at different concentrations Surface elements (0, 25, 50, 75, 100 μM) and pentapeptide (0, 3, 5, 8, 10 μM) were cultured for 24 hours; PBS: phosphate buffer solution; a, b, ab, c, d represents There is no statistical difference in the same symbol.

第6圖 表面素(SF)與五胜肽(PPP-3)對基質金屬蛋白酶(Matrix metallopeptidase 9)的抑制能力;基質金屬蛋白酶的量是以酵素免疫測定法(ELISA)來測量;小鼠胚胎纖維母細胞分別培養於不同濃度之五胜肽(0、3、5、8及10μM)與表面素(0、25、50、75及100μM);a,b,c代表若符號相同則沒有統計上之差異。 Figure 6: Surface metalloproteinase (SF) and pentapeptide (PPP-3) inhibit matrix metalloproteinase (Matrix metallopeptidase 9); matrix metalloproteinase is measured by enzyme immunoassay (ELISA); mouse embryo Fibroblasts were cultured in different concentrations of five peptides (0, 3, 5, 8 and 10 μM) and surface proteins (0, 25, 50, 75 and 100 μM); a, b, c represent no statistics if the symbols are the same The difference.

第7圖 表面素促進皮膚吸收皮質類固醇的測試;實驗分成兩組,控制組以PBS(pH=7.4)100μl混合異硫氰酸(fluorescein isothiocyanate,FITC)標記之皮質類固醇(dexamethasone),添加於1cm2無菌脫脂棉並以透氣貼布固定於小鼠背部;實驗組為以異硫氰酸標記之皮質類固醇添加0、0.2、0.5、1、2、5%的表面素來處理;實驗結果則以共軛焦顯微鏡觀偵測其螢光亮度;(A)~(F)圖依序為皮質類固醇添加0、0.2、0.5、1、2、5%表面素;SF:表面素。 Figure 7 Surface surface promotes skin absorption of corticosteroids; the experiment is divided into two groups. The control group is PBS (pH=7.4) 100 μl mixed with fluorescein isothiocyanate (FITC) labeled corticosteroid (dexamethasone), added to 1 cm. 2 Sterile absorbent cotton and fixed on the back of the mouse with a breathable patch; the experimental group was treated with isothiocyanate-labeled corticosteroids with 0, 0.2, 0.5, 1, 2, 5% surface elements; the experimental results were conjugated. The focal microscope was used to detect the fluorescence brightness; (A)~(F) was sequentially added to the corticosteroids with 0, 0.2, 0.5, 1, 2, 5% surface elements; SF: surface protein.

第8圖 表面素促進皮膚吸收保濕因子玻尿酸(HA)的測試。實驗分成兩組,控制組以PBS(pH=7.4)100μl混合異硫氰酸(fluorescein isothiocyanate,FITC)標記之玻尿酸(hyaluronic acid),添加於1cm2無菌脫脂棉,並以透氣貼布固定於小鼠背部。實驗組為以異硫氰酸標記之玻尿酸添加0、0.2、0.5、1、2、5%的表面素處理一小時;實驗結果則以共軛焦顯微鏡觀偵測其螢光亮度。(A)~(F)圖依序為玻尿酸添加0、0.2、0.5、1、2、5%的表面素;SF:表面素。 Figure 8 shows the test of the skin's absorption of the moisturizing factor hyaluronic acid (HA). The experiment was divided into two groups. The control group was PBS (pH=7.4) 100 μl mixed with fluorescein isothiocyanate (FITC)-labeled hyaluronic acid, added to 1 cm 2 sterile cotton wool, and fixed with a breathable patch. The back of the mouse. The experimental group was treated with isothiocyanate-labeled hyaluronic acid with 0, 0.2, 0.5, 1, 2, and 5% of surface keratin for one hour; the experimental results were observed by conjugated focal microscope to detect the fluorescence brightness. (A) ~ (F) map sequentially added 0, 0.2, 0.5, 1, 2, 5% of surface acid for hyaluronic acid; SF: surface element.

第9圖 表面素促進皮膚吸收保濕因子(γ-GPA)的測試;實驗分成兩組, 控制組以PBS(pH=7.4)100μl混合異硫氰酸(fluorescein isothiocyanate,FITC)標記之γ-GPA,添加於1cm2無菌脫脂棉並以透氣貼布固定於小鼠背部;實驗組以異硫氰酸標記之γ-GPA添加0、1%、2%、5%、10%、15%、20%之表面素處理一小時,實驗結果則以共軛焦顯微鏡觀偵測其螢光亮度;(A)~(G)圖依序為γ-GPA添加0、1%、2%、5%、10%、15%、20%的表面素。 Figure 9 Surface surface promotes skin absorption moisturizing factor (γ-GPA) test; the experiment is divided into two groups, the control group is PBS (pH = 7.4) 100μl mixed with fluorescein isothiocyanate (FITC) labeled γ-GPA, Add to 1 cm 2 sterile cotton wool and fix it on the back of the mouse with a breathable patch; the experimental group added 0, 1%, 2%, 5%, 10%, 15%, 20% with isothiocyanate-labeled γ-GPA. The surface element was treated for one hour, and the experimental results were detected by a conjugated focal microscope to detect the brightness of the fluorescence; (A)~(G) were sequentially added to the γ-GPA by 0, 1%, 2%, 5%, and 10%. , 15%, 20% of surface elements.

第10圖 表面素具促進奈米金經皮膚吸收的效果;奈米金的量是以螢光顯微鏡來測量;綠色螢光代表奈米金的存在,混合有表面素之奈米金實驗組可以於小鼠(BALB/c)真皮層發現有較多的奈米金;綠色亮點為毛囊自體螢光(hair follicles autofluorescence);SC surface:角質層(Stratum corneum)表面。 Figure 10 Surface surface promotes the absorption of nanogold through the skin; the amount of nanogold is measured by a fluorescence microscope; the green fluorescence represents the presence of nanogold, and the nanogold mixed with surface elements can More nanogold was found in the dermis of mice (BALB/c); green highlights were hair follicles autofluorescence; SC surface: stratum corneum surface.

第11圖 表面素之乳化力分析;將不同濃度的表面素溶於pH為6.4、7.4及8.4的緩衝溶液中,取出2ml並添加3ml柴油於試管中,以震盪(vortex)2分鐘,於室溫下靜置24小時後,測量其乳化指數(emulsification index,E24)。 Figure 11 Emulsion force analysis of surface factors; dissolve different concentrations of surface pigment in a buffer solution of pH 6.4, 7.4 and 8.4, take 2ml and add 3ml of diesel oil in a test tube, shake (vortex) for 2 minutes, in the room After standing for 24 hours under temperature, the emulsification index (E 24 ) was measured.

第12圖 表面素之起泡力分析;將不同濃度粗純化表面素溶於pH為7.4的緩衝溶液中,以震盪(vortex)兩分鐘後靜置1小時後,測量其泡沫高度,並計算其最大起泡密度(foam maximum density,MD)。 Figure 12: Foaming force analysis of surface pigments; different concentrations of crude purified surface pigment were dissolved in a buffer solution of pH 7.4, and after vortexing for two minutes, after standing for 1 hour, the foam height was measured and calculated. Maximum foam density (MD).

第13圖 顯示的為表面素濃度和起泡高度之間的關係。 Figure 13 shows the relationship between surface element concentration and foaming height.

第14圖 表面素濃度與濁度(Turbidity %)之間的關係。 Figure 14 shows the relationship between surface element concentration and turbidity (Turbidity %).

第15圖 稀釋於聚合物和界面活性劑複合物(polymer-surfactant complex)後,含有表面素的洗髮精會有沉澱的產生。 Figure 15 After dilution of the polymer-surfactant complex, surface-containing shampoos will precipitate.

本發明係以下面的實施例予以示範闡明,但本發明不受下述實施例所限制。其中以下各實施例係以具有以下特徵之表面素來實施:該表面素為一種環脂胜肽,且該表面素包括連接至β羥基脂肪酸(beta-hydroxy fatty acid)(連結13~15個碳氫鏈)之七胜肽序(L)Glu-(L)Leu-(D)Leu-(L)Val-(L)Asp-(D)Leu-(L)Leu;其中該脂肪酸之異C14約為37%。 The present invention is exemplified by the following examples, but the present invention is not limited by the following examples. The following examples are carried out by a surface element having the following characteristics: the surface element is a cyclolipin peptide, and the surface element comprises a beta-hydroxy fatty acid (linked to 13 to 15 hydrocarbons). Chain) of the seven-peptide sequence (L) Glu-(L)Leu-(D)Leu-(L)Val-(L)Asp-(D)Leu-(L)Leu; wherein the fatty acid has a different C14 37%.

實施例一 表面素對人類皮膚及小鼠胚胎纖維母細胞之抗老Example 1 Surface anti-aging of human skin and mouse embryonic fibroblasts 化試驗Chemical test

實驗材料與方法Experimental materials and methods

1. 實驗細胞株 Experimental cell strain

Human skin fibroblast(CCD-966SK)購自BCRC生物資源保存及研究中心-編號:60153。 Human skin fibroblast (CCD-966SK) was purchased from the BCRC Bioresource Conservation and Research Center - ID: 60153.

2. Mouse BALB/3T3 embryo(BALB/3T3 Clone A31)購自BCRC生物資源保存及研究中心-編號:60009。 2. Mouse BALB/3T3 embryo (BALB/3T3 Clone A31) was purchased from the BCRC Bioresource Conservation and Research Center - ID: 60009.

3. 實驗動物 3. Experimental animals

由國家實驗動物中心購得單一性別之BALB/cByJNarl品系小白鼠,體重約為200~250公克,飼養條件為人工光照每日12小時、濕度75%和溫度25℃,飼養於含空調設備之海洋大學生命科學動物房,並由專人照顧給予足夠的飼料及飲水。 The BALB/cByJNarl strain of single sex was purchased from the National Laboratory Animal Center and weighed about 200-250 grams. The breeding conditions were artificial light 12 hours a day, humidity 75% and temperature 25 ° C. It was raised in the ocean with air-conditioning equipment. The University Life Science Animal Room is cared for by a dedicated person to give enough feed and water.

4. 抗老化基因表現量測試 4. Anti-aging gene performance test

(1)人類及小鼠基因cDNA序列選殖 (1) Human and mouse gene cDNA sequence selection

本實驗利用TRIzol reagent(Invitrogen,USA)抽取人類皮膚纖維母細胞及小鼠胚胎纖維母細胞之Total RNA,經RNA電泳分析後;利用反轉錄聚合酶連鎖反應(RT-PCR)進行人類皮膚纖維母細胞sirtuin 1、sirtuin 3及小鼠胚胎纖維母細胞sirtuin 1基因序列的選殖;並由基因資料庫(GeneBank)尋找已知之sirtuins基因序列,利用GCG program尋找相似性高的序列,設計一對引子(Primer),進行聚合酶連鎖反應(Polymerase chain reaction,PCR);再取一小部分反應產物經由1.2%膠體電泳分析,當出現與預期基因片段大小相符的產物時,將所剩下的產物經由低熔點瓊脂膠體電泳後,將所需膠體的產物由膠體上切下,進行膠體萃取以取得純化的特定大小DNA片段,此純化片段與選殖載體pGEM-T-easy vector(pGEM-T-easy cloning kit,Promega,USA)進行接合反應,再轉型入勝任細胞中;最後經由小量培養後,抽取選殖載體進行定序,將序列資料利用美國生物資訊中心(NCBI)網站之BLAST程式進行比對。經由 以上步驟選殖出正確的部分人類皮膚纖維母細胞sirtuin 1、sirtuin 3及小鼠胚胎纖維母細胞sirtuin 1 cDNA序列的選殖株後,將選殖株再次轉型入勝任細胞中複製,並抽取高純度質體保存,以便進行後續實驗。 This experiment used TRIzol reagent (Invitrogen, USA) to extract Total RNA from human skin fibroblasts and mouse embryonic fibroblasts, and analyzed by RNA electrophoresis; human skin fibrils were performed by reverse transcription polymerase chain reaction (RT-PCR). The sirtuin 1, sirtuin 3 and mouse embryonic fibroblast sirtuin 1 gene sequence was selected; and the known sirtuins gene sequence was searched by gene bank (GeneBank), and the similar sequence was searched by GCG program to design a pair of primers. (Primer), performing a polymerase chain reaction (PCR); a small portion of the reaction product is analyzed by 1.2% colloidal electrophoresis. When a product corresponding to the size of the expected gene fragment appears, the remaining product is passed through After electrophoresis of the low melting point agar colloid, the product of the desired colloid is excised from the colloid and subjected to colloidal extraction to obtain a purified DNA fragment of a specific size. The purified fragment and the selection vector pGEM-T-easy vector (pGEM-T-easy The cloning kit, Promega, USA) is ligated into a competent cell; finally, after a small amount of culture, the selection vector is selected for sequencing. Sequence information using the BLAST program American Center for Biological Information (NCBI) website for comparison. via After the above steps, the correct part of human skin fibroblast sirtuin 1, sirtuin 3 and mouse embryonic fibroblast sirtuin 1 cDNA sequence were selected, and the selected strain was transformed into competent cells for replication and high extraction. Purity plastids are preserved for subsequent experiments.

(2)細胞Total RNA之萃取 (2) Extraction of cellular Total RNA

RNA在自然環境中容易受到RNase的分解,所以實驗前必須將所用的器具以高溫滅菌,並在烘箱中烘乾。在操作過程中配戴手套及口罩。取欲進行實驗之細胞實驗組,迅速將800μL TRIzolTM reagent加入培養皿中,再將沖洗下來之細胞液放置於滅菌Tube中,加入所使用TRIzolTM reagent總體積1/5的氯仿(Chloroform),強力搖晃30秒,於室溫下靜置15分鐘,再於4℃以13200rpm離心15分鐘,將上清液抽出至新的1.5mL微量離心管中。此時RNA會溶於上清液的水層中,將上清液吸入另一個乾淨的1.5mL微量離心管中,加入所使用TRIzolTM reagent體積1/2的異丙醇(Isopropanol)及高鹽溶液(1.2M Sodium Chloride及0.8M Sodium citrate),均勻搖晃後於-20℃下靜置30分鐘,再於4℃以13200rpm離心15分鐘以沉澱RNA;小心的移除上清液,先加入800μL的100%絕對酒精搖晃沖洗後,於4℃以13200rpm離心10分鐘後,移除100%酒精。小心吸取並移除上清液,以55℃乾燥RNA沉澱物5分鐘。將沉澱物溶解在15μL DEPC水中。置於55℃下10分鐘以溶解RNA,最後儲存在-80℃冷凍冰櫃中備用。 RNA is easily decomposed by RNase in the natural environment, so the equipment used must be sterilized at high temperature and dried in an oven before the experiment. Wear gloves and a mask during operation. For the cell experiment group to be tested, 800 μL of TRIzolTM reagent was quickly added to the culture dish, and the washed cell liquid was placed in a sterilized Tube, and chloroform (Chloroform) of 1/5 of the total volume of TRIzolTM reagent was added, and the mixture was vigorously shaken. After 30 seconds, it was allowed to stand at room temperature for 15 minutes, and then centrifuged at 13200 rpm for 15 minutes at 4 ° C, and the supernatant was withdrawn into a new 1.5 mL microcentrifuge tube. At this point, the RNA will be dissolved in the aqueous layer of the supernatant, and the supernatant will be inhaled into another clean 1.5 mL microcentrifuge tube. Isopropanol and high salt solution of 1/2 volume of TRIzolTM reagent will be added. (1.2M Sodium Chloride and 0.8M Sodium citrate), shake evenly at -20 °C for 30 minutes, then centrifuge at 13200 rpm for 15 minutes at 4 °C to precipitate RNA; carefully remove the supernatant, first add 800 μL After 100% absolute alcohol shaking and rinsing, after centrifugation at 13200 rpm for 10 minutes at 4 ° C, 100% alcohol was removed. The supernatant was carefully aspirated and removed, and the RNA pellet was dried at 55 ° C for 5 minutes. The precipitate was dissolved in 15 μL of DEPC water. The RNA was dissolved at 55 ° C for 10 minutes and finally stored in a -80 ° C freezer for later use.

(3)RNA濃度與純度的測量 (3) Measurement of RNA concentration and purity

以分光光度計測量OD260,計算RNA濃度的標準為1 OD260=40μg of RNA/mL,其公式40μg×dilute factor×A260=μg/mL。RNA純度以OD260/OD280的比值為依據,比值介於1.9~2.0之間為純度較高的RNA。 The OD260 was measured by a spectrophotometer, and the standard for calculating the RNA concentration was 1 OD260 = 40 μg of RNA/mL, and the formula was 40 μg × dilute factor × A260 = μg / mL. RNA purity is based on the ratio of OD260/OD280, and the ratio is between 1.9 and 2.0 for higher purity RNA.

(4)反轉錄(Reverse Transcription,RT) (4) Reverse Transcription (RT)

取5μg之Total RNA於200μL微量離心管中並以DEPC水將 總體積調整至13μL,加入1μL之oligo(dT)18、10mM dNTPs,置於冰上。再加入5×AMV buffer 4μl及AMV 1μl(40units/μL),均勻混合,於42℃反應60分鐘以合成cDNA,再以70℃作用10分鐘以終止反應。 Take 5 μg of Total RNA in a 200 μL microcentrifuge tube and use DEPC water. The total volume was adjusted to 13 μL, and 1 μL of oligo(dT)18, 10 mM dNTPs was added and placed on ice. Further, 5 μM of 5×AMV buffer and 1 μl of AMV (40 units/μL) were added, uniformly mixed, and reacted at 42° C. for 60 minutes to synthesize cDNA, and then reacted at 70° C. for 10 minutes to terminate the reaction.

(5)聚合酶連鎖反應(Polymerase chain reaction,PCR) (5) Polymerase chain reaction (PCR)

將RT做好的cDNA模板(Template),以Taq polymerase進行聚合酶連鎖反應(Polymerase Chain Reaction,PCR)擴增分析。取1μL cDNA加入0.5μL的10mM dNTPs、2.5μl的10×PCR buffer、專一性引子(Gene specific primer,GSP)各0.5μL及0.25μL Taq polymerase,並加入二次滅菌水將總體積調整至25μL。將反應管置入PCR反應器(DNA thermal cycler;Applied Biosystems 2720 Thermal Cycler)中,設定以下條件反應:94℃解離2分鐘;94℃解離30秒;64℃黏合30秒;72℃合成1分鐘;解離、黏合、合成步驟重複30個循環後保存在4℃下。取反應後的PCR產物5~15μL,以1.5%瓊脂膠體進行電泳分析,經溴化乙錠(EtBr)染色10分鐘後,以水退染約10分鐘,置於照相系統Digital Gel Image System擷取影像,並以UN-SCAN-IT gel-Gel Analysis Software Version 6.1定量分析。 A cDNA template (RT) prepared by RT was subjected to polymerase chain reaction (PCR) amplification analysis using Taq polymerase. 1 μL of cDNA was added to 0.5 μL of 10 mM dNTPs, 2.5 μl of 10× PCR buffer, Gene specific primer (GSP) of 0.5 μL and 0.25 μL of Taq polymerase, and the total volume was adjusted to 25 μL by adding secondary sterilized water. The reaction tube was placed in a PCR reactor (DNA thermal cycler; Applied Biosystems 2720 Thermal Cycler), and the following conditions were set: dissociation at 94 ° C for 2 minutes; dissociation at 94 ° C for 30 seconds; bonding at 64 ° C for 30 seconds; synthesis at 72 ° C for 1 minute; The dissociation, bonding, and synthesis steps were repeated for 30 cycles and stored at 4 °C. 5~15μL of the PCR product after reaction was analyzed by electrophoresis in 1.5% agar colloid. After staining with ethidium bromide (EtBr) for 10 minutes, it was deproteinized with water for about 10 minutes and placed in the camera system Digital Gel Image System. Image and quantitative analysis by UN-SCAN-IT gel-Gel Analysis Software Version 6.1.

(6)即時定量聚合酶連鎖反應(Real-time quantitative PCR) (6) Real-time quantitative PCR

利用螢光染劑SYBR green I可鑲嵌在DNA雙股凹槽上,經由鹵素燈激發而產生螢光的特性,偵測其螢光值的量。當SYBR green I沒有鑲嵌在雙股DNA上時,螢光背景值非常低;當SYBR green I開始鑲嵌在PCR放大的標的基因片段上時,螢光值訊號也會相對的提高。如無非特異性引子的結合,或Genomic DNA的污染等干擾影響,PCR反應合成標的基因的狀態可區分為的DNA合成為兩倍倍增的幾何級數倍增期(Geometric phase),與反應物不足,基因合成非兩倍倍增的線性增加期(Linear phase);以及最後反應物耗盡、失效,達反應終點的高原期(Plateau phase)。因此要偵測標的基因在組織器官的表現量, 必須在PCR反應的幾何級數倍增期定量才具有意義。Real-time quantitative PCR的原理就是利用不同濃度模板在相同PCR反應條件下,含有高濃度模板的反應會較快達到幾何級數倍增期,相對的低濃度的模板則較慢達到,將定義達到幾何級數倍增期中點的臨界PCR循環數目定為CT(Thresholdcycle),也就是說CT值會隨模板濃度降低而升高。利用不同濃度標準品在同步定量PCR反應的CT值,由軟體計算繪製標準曲線與回歸公式,以內插法換算代測樣品內含有標的基因絕對表現量。同時若要得到Melting Curve,則在標的基因放大循環後進行melting temperature 40℃~99℃的連續螢光偵測,分析melting curve的結果可以瞭解引子是否會自行有互補的現象,或是引子的專一性,以更正確的幫助了解實驗定量的正確性。 The fluorescent dye SYBR green I can be embedded in the double groove of the DNA, and the fluorescent light is excited by the halogen lamp to detect the amount of fluorescence. When SYBR green I is not embedded in double-stranded DNA, the fluorescent background value is very low; when SYBR green I is first embedded in the PCR-amplified target gene fragment, the fluorescence value signal is also relatively increased. If there is no interference of non-specific primers or interference of Genomic DNA, the state of the PCR-synthesized target gene can be distinguished by a two-fold multiplication of geometric phase and insufficient reactants. Gene synthesis is not a two-fold multiplication linear phase; and finally the reactants are depleted, failed, and reach the Plateau phase of the end of the reaction. Therefore, to detect the amount of expression of the target gene in tissues and organs, It must be quantified to quantify the geometric progression of the PCR reaction. The principle of Real-time quantitative PCR is to use a different concentration of template under the same PCR reaction conditions, the reaction containing high concentration of template will reach the geometric multiplication period faster, and the relatively low concentration template will be reached slowly, and the definition will reach the geometry. The number of critical PCR cycles at the midpoint of the series multiplication period is determined as CT (Threshold Cycle), which means that the CT value increases as the template concentration decreases. Using the CT values of the simultaneous quantitative PCR reactions of different concentration standards, the standard curve and the regression formula were calculated by software, and the absolute expression of the target gene contained in the sample was calculated by interpolation. At the same time, if you want to get Melting Curve, you can perform continuous fluorescence detection at 40 °C~99 °C after the target gene amplification cycle. The results of melting curve can be used to understand whether the primers have complementary phenomena or the specificity of the primers. Sex, to better understand the correctness of experimental quantification.

將96 well PCR plate放置在4℃預冷的96 well PCR plate專用冰盒上,分別加入10μL SYBR green、各4μL之Real-time PCR專一性引子(表一),最後加入2μL之RT產物作為PCR反應之模板,貼上96 well PCR plate專用膜後置於4℃離心機中以1500rpm離心3分鐘,將樣品離心至PCR plate底部。將PCR plate置入即時定量PCR反應器中(Roche lightcycler 480 Real time PCR)中,設定以下反應條件:熱啟動(Hot start)反應以95℃反應5分鐘;擴增反應(Amplification)以95℃解離30秒、60℃黏合30秒,進行40個循環;並連續偵測螢光值,以判斷擴增的產物是否皆為相同的解離溫度。完成反應後將反應數據以Roche軟體進行分析。實驗所得之數據,以SPSS軟體,運用單變量分析(One-way analysis of variance),依Duncan’s Multiple Range Test比較各因子間顯著差異程度(p<0.05),所得數據以平均值±標準偏差(Mean±SD)表示。 The 96 well PCR plate was placed on a pre-cooled 96 well PCR plate ice box at 4 °C, and 10 μL of SYBR green and 4 μL of Real-time PCR specific primers were added (Table 1). Finally, 2 μL of RT product was added as PCR. The template of the reaction was attached to a 96 well PCR plate membrane and placed in a 4 ° C centrifuge for 3 minutes at 1500 rpm, and the sample was centrifuged to the bottom of the PCR plate. The PCR plate was placed in a real-time quantitative PCR reactor (Roche lightcycler 480 Real time PCR), and the following reaction conditions were set: hot start reaction was carried out at 95 ° C for 5 minutes; amplification reaction (Amplification) was dissociated at 95 ° C 40 seconds, 60 ° C bonding for 30 seconds, 40 cycles; and continuously detect the fluorescence value to determine whether the amplified products are the same dissociation temperature. After completion of the reaction, the reaction data was analyzed in Roche software. The data obtained from the experiment were analyzed by SPSS software using One-way analysis of variance, and the degree of significant difference between the factors was compared according to Duncan's Multiple Range Test (p<0.05). The obtained data were average±standard deviation (Mean). ±SD) representation.

表一Real-time PCR專一性引子 Table 1 Real-time PCR specific primer

結果表面素促進小鼠胚胎纖維母細胞之長壽基因(sertuin 1基因)表現和增殖Results Surface element promotes the expression and proliferation of longevity gene (sertuin 1 gene) in mouse embryonic fibroblasts

由第1圖可知,表面素可以促進小鼠胚胎纖維母細胞之長壽基因(sertuin 1基因)的表現;當給予小鼠胚胎纖維母細胞不同濃度之表面素時,不同濃度的表面素對於sertuin 1基因的表現,具有不同之效果;當給予小鼠胚胎纖維母細胞表面素6小時後,50μM、75μM的表面素具有促進sertuin 1基因表現之效果;當給予小鼠胚胎纖維母細胞表面素12小時後,25μM的表面素具有促進sertuin 1基因表現之效果;當給予小鼠胚胎纖維母細胞表面素36時後,50μM、100μM的表面素具有促進sertuin 1基因表現之效果;當給予小鼠胚胎纖維母細胞表面素48後,50μM的表面素具有促進sertuin 1基因表現之效果。其中50μM的表面素對於促進sertuin 1基因的表現,具有最好的效果。 As can be seen from Fig. 1, surface stimulants can promote the expression of the longevity gene ( sertuin 1 gene) of mouse embryonic fibroblasts; when different concentrations of surface elements are administered to mouse embryonic fibroblasts, different concentrations of surface elements for sertuin 1 Gene expression has different effects; when administered to mouse embryonic fibroblast surface hormone for 6 hours, 50μM, 75μM surface element has the effect of promoting sertuin 1 gene expression; when mouse embryonic fibroblast surface factor is administered for 12 hours After that, 25 μM of surface element has the effect of promoting the expression of sertuin 1 gene; when the mouse embryonic fibroblast surface element 36 is administered, 50 μM, 100 μM of surface element has the effect of promoting the expression of sertuin 1 gene; when the mouse embryonic fiber is administered After the parent cell surface 48, 50 μM of surface element has the effect of promoting the expression of the sertuin 1 gene. Among them, 50 μM of surface hormone has the best effect on promoting the performance of sertuin 1 gene.

第2圖為白藜蘆醇(Resveratrol)、五胜肽(Palmitoyl pentapeptide-3)及表面素對小鼠胚胎纖維母細胞之增殖的影響;由第2圖可以得知表面素具有促進小鼠胚胎纖維母細胞增殖的效果,且以75μM的表面素促進細胞增殖 的效果最佳,50μM的表面素促進細胞增殖的效果次佳。另,表面素促進細胞增殖的效果亦較白藜蘆醇和五胜肽佳。 Figure 2 shows the effects of Resveratrol, Palmitoyl pentapeptide-3 and surface hormone on the proliferation of mouse embryonic fibroblasts; Figure 2 shows that surface proteins promote mouse embryos. The effect of fibroblast proliferation, and promotes cell proliferation with 75 μM surface protein The best effect is that the 50 μM surface element promotes cell proliferation with the second best effect. In addition, the effect of surface stimulating cells on cell proliferation is better than that of resveratrol and pentapeptide.

實施例二 表面素具有抗光老化與抗氧化作用Example 2 Surface elements have anti-photoaging and anti-oxidation effects

1. 表面素具有抗光老化修護功能 1. Surface element has anti-photoaging repair function

將細胞分盤後,培養4小時使其固定於培養皿後,以UV-A波長之紫外線燈管作為光緊迫來源,於紫外光雜交箱中對實驗細胞照射其能量濃度為0J/cm2、10J/cm2及15J/cm2,照射後添加25、50、75、100及125μM濃度之表面素,培養24小時後,以MTT法測試細胞活存率。 After the cells were plated, cultured for 4 hours and fixed in a culture dish, the UV-A wavelength ultraviolet light tube was used as a light source, and the experimental cells were irradiated with an energy concentration of 0 J/cm 2 in an ultraviolet light hybridization box. 10 J/cm 2 and 15 J/cm 2 were added, and surface concentrations of 25, 50, 75, 100, and 125 μM were added after the irradiation, and after 24 hours of culture, the cell survival rate was measured by the MTT method.

由第3圖可知,表面素具有抗光老化修護功能;當給予小鼠胚胎纖維母細胞照射10J/cm2之紫外光後,25、50、75、100及125μM濃度之表面素皆具有增加細胞存活率的效果,且以75μM濃度之表面素效果最佳;當給予小鼠胚胎纖維母細胞照射15J/cm2之紫外光後,25、50、75、及100μM濃度之表面素皆具有增加細胞存活率的效果,且以50μM濃度之表面素效果最佳。 It can be seen from Fig. 3 that the surface element has anti-photoaging repair function; when the mouse embryonic fibroblast is irradiated with ultraviolet light of 10 J/cm 2 , the surface elements at 25, 50, 75, 100 and 125 μM concentration are increased. The effect of cell survival rate was the best at 75 μM concentration; when the mouse embryonic fibroblasts were irradiated with 15 J/cm 2 of ultraviolet light, the surface elements at 25, 50, 75, and 100 μM concentrations increased. The effect of cell viability was the best, and the surface effect at a concentration of 50 μM was the best.

2. 表面素具有抗氧化修護功能 2. Surface element has anti-oxidation repair function

將小鼠胚胎纖維母細胞分盤後,培養4小時使其固定於培養皿後,以過氧化氫作為氧化緊迫來源;細胞以100、150、200及250μM濃度的過氧化氫處理後,再添加25、50、75及100μM濃度之表面素,培養24小時,然後以MTT法測試細胞活存率。 The mouse embryonic fibroblasts were plated, cultured for 4 hours to be fixed in a culture dish, and hydrogen peroxide was used as an urgent source of oxidation; the cells were treated with hydrogen peroxide at concentrations of 100, 150, 200, and 250 μM, and then added. Surface proteins at concentrations of 25, 50, 75 and 100 μM were cultured for 24 hours and then tested for cell viability by MTT assay.

由第4圖可知,表面素可以增加以過氧化氫處理過之小鼠胚胎纖維母細胞的存活率。其中25、50、75μM濃度之表面素皆有良好之效果,而75μM濃度之表面素的效果最為顯著。 As can be seen from Fig. 4, the surface element can increase the survival rate of mouse embryonic fibroblasts treated with hydrogen peroxide. Among them, 25, 50, 75 μM concentration of surface elements have a good effect, while the 75 μM concentration of surface elements has the most significant effect.

實施例三 表面素對小鼠胚胎纖維母細胞之膠原蛋白增長效果Example 3 Effect of surface element on collagen growth of mouse embryonic fibroblasts

1.膠原蛋白濃度分析 1. Collagen concentration analysis

使用膠原蛋白濃度分析套組(SircolTM soluble collagen assay kit)分析培養基中膠原蛋白總濃度。分析方法簡述如下: The collagen concentration analysis kit (Sircol TM soluble collagen assay kit) were analyzed for total collagen concentration in the medium. The analysis method is briefly described as follows:

取待分析樣品與不同濃度之標準品0.1mL置於1.5mL離心管。加入1mL dye reagent,以震盪混合器振盪35min。離心12000rpm 10min,倒去上清液。小心的以吸水紙除去離心管邊緣的殘留液,勿碰觸沉澱物。加入1mL Alkali reagent溶解沉澱物,呈色穩定後取出0.2mL置入96孔盤,以ELISA reader讀取吸光值570nm。 The sample to be analyzed and 0.1 mL of different concentrations of the standard were placed in a 1.5 mL centrifuge tube. Add 1 mL of dye reagent and shake with a vibrating mixer for 35 min. Centrifuge at 12000 rpm for 10 min and pour off the supernatant. Carefully remove the residual liquid from the edge of the tube with absorbent paper and do not touch the sediment. The precipitate was dissolved by adding 1 mL of Alkali reagent, and after color stabilization, 0.2 mL was taken out and placed in a 96-well plate, and the absorbance at 570 nm was read by an ELISA reader.

2. 表面素具有增加小鼠胚胎纖維母細胞之膠原蛋白的效果 2. Surface elements have the effect of increasing the collagen of mouse embryonic fibroblasts

由第5圖可知,表面素可以增加小鼠胚胎纖維母細胞之膠原蛋白的增生;與給予磷酸鹽緩衝溶液(Phosphate buffered saline,PBS)培養之對照組相比較,25、50、75及100μM之表面素對於增加細胞內之膠原蛋白,皆有很好的效果,而其中以100μM的效果最佳。而五胜肽(Palmitoyl pentapeptide-3,PPP-3)亦能夠增加細胞內之膠原蛋白含量,但其效果與表面素相比較,表面素之效果似乎較好。 As can be seen from Fig. 5, surface keratin can increase the proliferation of collagen in mouse embryonic fibroblasts; compared with the control group cultured with Phosphate buffered saline (PBS), 25, 50, 75 and 100 μM Surface elements have a good effect on increasing intracellular collagen, and 100 μM is the best. The Panmitoyl pentapeptide-3 (PPP-3) can also increase the collagen content in the cells, but the effect of the surface elements seems to be better than that of the surface substances.

實施例四 表面素具有抑制基質金屬蛋白酶(Matrix metallopeptidase 9)的效果Example 4 Surface elements have the effect of inhibiting matrix metallopeptide 9

1. 基質金屬蛋白酶(Matrix metallopeptidase 9)抑制效果測定 1. Matrix metalloproteinase (Matrix metallopeptidase 9) inhibition effect determination

將小鼠胚胎纖維母細胞培養分盤後,加入商用活性抗皺物質3、5、8及10μM Palmitoyl pentapeptide-3)與加入25、50、75及100μM表面素進行比較,分析方式為以Abnova MMP-9(Mouse)ELISA Kit和ELISA Reader進行細胞中基質金屬蛋白酶九型的濃度分析。 After the mouse embryonic fibroblasts were cultured, the commercial active anti-wrinkle substances 3, 5, 8 and 10 μM Palmitoyl pentapeptide-3 were added and compared with the addition of 25, 50, 75 and 100 μM surface elements by Abnova MMP- 9 (Mouse) ELISA Kit and ELISA Reader were used to analyze the concentration of matrix metalloproteinase 9 in cells.

2. 表面素具有抑制基質金屬蛋白酶的效果 2. Surface element has the effect of inhibiting matrix metalloproteinase

由第6圖可知,50、75及100μM的表面素具有抑制基質金屬蛋白酶的效果;且以50μM的表面素抑制效果最佳。 As can be seen from Fig. 6, surface molecules of 50, 75 and 100 μM have an effect of inhibiting matrix metalloproteinase; and the surface inhibitory effect at 50 μM is optimal.

實施例五 表面素促進化妝品原料皮膚穿透Example 5 Surface element promotes skin penetration of cosmetic raw materials

1. 實驗方法 Experimental method

實驗進行前,先進行背部剃毛的動作。將6-8週小白鼠以麻醉劑舒泰(Zoletil)進行腹腔注射將麻醉,使動物躺平後,用電動剃毛刀輕柔地將背部的毛剃除,以脫毛膏去除剩餘體毛。並將動物安置在有保暖燈的籠子(cage)中,並且給予飲水照顧。實驗前,以舒泰(Zoletil)將小白鼠進行麻醉。實驗分成兩組,控制組以PBS(pH=7.4)100μl混合異硫氰酸(fluorescein isothiocyanate,FITC)標記之玻尿酸(hyaluronic acid)或皮質類固醇(dexamethasone),添加於1cm2無菌脫脂棉並以透氣貼布固定於小鼠背部。實驗組則以玻尿酸或皮質類固醇各添加0.2、0.5、1、2、5% surfactin處理。 Before the experiment, the back shaving action was performed. The 6-8 week mice were anesthetized by intraperitoneal injection with an anesthetic Zoletil. After the animals were laid flat, the back hair was gently shaved with an electric razor, and the remaining body hair was removed with a depilatory cream. The animals are placed in a cage with a warm light and given care of the drinking water. Prior to the experiment, the mice were anesthetized with Zoletil. The experiment was divided into two groups. The control group was PBS (pH=7.4) 100 μl mixed with fluorescein isothiocyanate (FITC)-labeled hyaluronic acid or dexamethasone, added to 1 cm 2 sterile cotton wool and ventilated. The cloth was fixed to the back of the mouse. The experimental group was treated with hyaluronic acid or corticosteroids with 0.2, 0.5, 1, 2, and 5% surfactin.

處理一小時後將小鼠以CO2窒息法犧牲小鼠,以酒精將皮膚上殘留的藥品清理,剪下小鼠背部皮膚,以Optimum cutting temperature compound(O.C.T)(SAKURA®,Japen)包埋後進行冷凍切片(CM-2000,Leica,Germany)。 One hour after the treatment, the mice were sacrificed by CO 2 asphyxiation, the residual drug on the skin was cleaned with alcohol, and the back skin of the mouse was cut out and embedded in Optimum cutting temperature compound (OCT) (SAKURA®, Japen). Frozen sections (CM-2000, Leica, Germany) were performed.

2. 表面素可促進皮質類固醇穿透皮膚 2. Surface substances can promote the penetration of corticosteroids into the skin

由第7圖可知,表面素可促進皮質類固醇穿透皮膚;藉由觀察螢光的強度,可以知道各實驗組中皮質類固醇穿透皮膚的量;螢光強度越強者,代表其穿透皮膚的皮質類固醇量越多;其中第7圖中之(B)、(C)、(D)、(E)可觀察到較對照組(A)多的螢光;也就是說,0.2、0.5、1、2%的表面素可以增加皮質類固醇穿透皮膚的量。 As can be seen from Figure 7, surface keratin can promote the penetration of corticosteroids into the skin; by observing the intensity of the fluorescence, the amount of corticosteroid penetration into the skin can be known in each experimental group; the stronger the fluorescence intensity, the penetration of the skin. The greater the amount of corticosteroids; (B), (C), (D), (E) in Figure 7 can be observed more fluorescence than the control group (A); that is, 0.2, 0.5, 1, 2% of surface substances can increase the amount of corticosteroids penetrating the skin.

3. 表面素促進皮膚吸收保濕因子玻尿酸(HA) 3. Surface pigment promotes skin absorption and moisturizing factor hyaluronic acid (HA)

由第8圖可知,表面素可促進皮膚吸收玻尿酸;螢光強度越強者,代表其穿透皮膚的玻尿酸量越多;其中以第8圖中之(A)所觀察到的螢光強度最強;意即1%的表面素促進皮膚吸收保濕因子玻尿酸的效果最佳。 As can be seen from Fig. 8, the surface element can promote the absorption of hyaluronic acid in the skin; the stronger the fluorescence intensity, the more the amount of hyaluronic acid that penetrates the skin; the fluorescence intensity observed by (A) in Fig. 8 is the strongest. That means that 1% of the surface pigment promotes the skin's absorption of the moisturizing factor hyaluronic acid.

4. 表面素促進皮膚吸收保濕因子聚麩胺酸(Gamma-polyglutamic acid,γ-GPA) 4. Surface pigment promotes skin absorption and absorption of glutamic acid (Gamma-polyglutamic acid, γ-GPA)

由第9圖可知,表面素可促進皮膚吸收保濕因子(γ-GPA);螢光強度越強者,代表皮膚吸收的聚麩胺酸量越多;其中第9圖中之(B)、(C)、(D)、(E)、(F)、(G)皆可觀察到較對照組(A)多的螢光;也就是說,1、2、5、10、10、15、20%的表面素皆可以增加皮膚吸收聚麩胺酸的量。 It can be seen from Fig. 9 that surface stimulating substances can promote skin absorption and moisturizing factor (γ-GPA); the stronger the fluorescence intensity, the more the amount of polyglutamic acid absorbed by the skin; (B) in Fig. 9 ( More fluorescence can be observed in C), (D), (E), (F), (G) than in the control group (A); that is, 1, 2, 5, 10, 10, 15, 20 % of the surface pigments can increase the amount of polyglutaric acid absorbed by the skin.

5.表面素促進奈米金(gold-nanoparticles,2nm)經由皮膚的吸收 5. Surface element promotes the absorption of gold-nanoparticles (2nm) through the skin.

當我們使用奈米金與表面素混合塗抹於老鼠表皮後,經一段時間,摘取皮膚進行冷凍切片,由於奈米金可自行發光,因此可直接以光學顯微鏡觀察奈米金在皮膚表皮層與真皮層之螢光含量。結果顯示使用傳統工藝乳化得到的護膚品膏體,其內部結構為膠團狀或膠束狀,因此不利於皮膚吸收奈米金,奈米金僅在表皮層被發現。而於添加12.5ppm表面素後,可顯著促進奈米金經由皮膚吸收的效果(第10圖)。 When we use nano gold and surface pigment to smear on the mouse epidermis, after a period of time, the skin is taken for cryosection. Since nano gold can self-illuminate, it can directly observe the nano-gold in the skin epidermis with an optical microscope. Fluorescence content of the dermis layer. The results show that the skin cream obtained by the emulsification of the conventional process has an internal structure of micelle or micelle, which is disadvantageous for the skin to absorb nano gold, and nano gold is only found in the epidermis. The addition of 12.5 ppm of surface pigment significantly promoted the absorption of nanogold through the skin (Fig. 10).

由以上研究結果可知,本案表面素可以取代化學合成的界面活性劑,廣泛應用於經皮給藥系統。 It can be seen from the above research results that the surface element can replace the chemically synthesized surfactant and is widely used in the transdermal drug delivery system.

實施例六 表面素乳化力分析Example 6 Surface emulsification analysis

乳化指數為界面活性劑的重要指標之一,本發明參考Cooper等人所使用的方法,測量界面活性劑對柴油的乳化指數。將不同濃度粗純化表面素溶於pH為6.4、7.4及8.4的緩衝溶液中,取出2ml並添加3ml柴油於試管中,以震盪(vortex)2分鐘,於室溫下靜置24小時,測量乳化層高度與溶液總高度之比值乘上100%即為該待測液之乳化指數。油品乳化能力之大小以乳化指數(emulsification index,E24)表示之,其中E24的公式如下所列: The emulsification index is one of the important indexes of the surfactant. The emulsification index of the surfactant to diesel oil is measured by the method used by Cooper et al. Different concentrations of crude purified surface pigment were dissolved in a buffer solution of pH 6.4, 7.4 and 8.4, 2 ml was taken out and 3 ml of diesel oil was added to the test tube, vortexed for 2 minutes, and allowed to stand at room temperature for 24 hours, and the emulsion was measured. The ratio of the height of the layer to the total height of the solution multiplied by 100% is the emulsification index of the liquid to be tested. The emulsification capacity of the oil is expressed by the emulsification index (E 24 ), and the formula of E 24 is as follows:

由第11圖可知表面素於pH=7.4時,具有較佳的乳化力,且當表面素於 pH=7.4和160μg/ml濃度時,具有最佳之乳化力。 It can be seen from Fig. 11 that the surface element has a better emulsifying power at pH=7.4, and when the surface is The optimum emulsifying power is obtained at pH=7.4 and 160 μg/ml.

實施例七 表面素可作為起泡劑Example 7 Surface element can be used as a foaming agent

1. 起泡力分析 Foaming force analysis

界面活性劑具有低起泡性的特性,本發明即為測試粗純化的表面素是否具起泡性。參考Razafindralambo等人所使用的方法,將不同濃度粗純化表面素溶於pH為7.4的緩衝溶液中,以震盪(vortex)兩分鐘後靜置1小時,測量其泡沫高度。起泡力以最大起泡密度(foam maximum density,MD)表示,將總液體高度除以最大起泡高度即可得到最大起泡密度。 The surfactant has the property of low foaming property, and the present invention is to test whether the crude purified surface element has foaming property. Referring to the method used by Razafindralambo et al., different concentrations of crude purified surface flavonoids were dissolved in a buffer solution having a pH of 7.4, and allowed to stand for 1 hour after shaking for 2 minutes, and the foam height was measured. The foaming force is expressed by the maximum foam density (MD), and the maximum foaming density is obtained by dividing the total liquid height by the maximum foaming height.

2. 表面素可作為起泡劑 2. Surface element can be used as a foaming agent

表面素具有許多生物特性,包含一般界面活性劑皆有的起泡及乳化能力(Razafindralambo et al.,1998)。所謂起泡現象是指,表面素會存在於氣相及液相的界面中,劇烈搖晃使界面活性劑將空氣抓下,形成內含空氣的薄膜(Halling,1981)。本發明測試Bacillus subtilis TH生產的表面素是否具有起泡之活性,結果顯示加入大於150μg的表面素於緩衝液中,MD值沒有明顯下降,最低MD值為1.23(見第12圖);推測可能是添加於去離子水中的表面素濃度已達臨界微胞濃度(Critical micelle concentration,CMC),表面素形成微胞狀,只剩下單體在溶液中作用。第13圖顯示的為表面素濃度和起泡高度之間的關係。Razafindralambo等人指出,表面素最低MD值可達0.10,和伊枯草菌素相比,表面素具有較優異的起泡效果,推測是和兩者之間的結構有關係,表面素屬於陰離子界面活性劑,且其脂肪酸碳鏈較短,而伊枯草桿菌素則為非離子界面活性劑,脂肪酸碳鏈較長(Razafindralambo et al.,1998)。Bacillus subtilis TH生產的表面素具有起泡能力,可當應用於清潔劑、洗髮精、洗手乳等個人保養品。 Surface elements have many biological properties, including the ability to foam and emulsify common surfactants (Razafindralambo et al., 1998). The so-called foaming phenomenon means that surface elements are present in the interface between the gas phase and the liquid phase, and the shaking is vigorously caused to cause the surfactant to catch the air to form a film containing air (Halling, 1981). The present invention tests whether the surface element produced by Bacillus subtilis TH has foaming activity, and the results show that the addition of more than 150 μg of surface element in the buffer has no significant decrease in MD value, and the lowest MD value is 1.23 (see Fig. 12); The concentration of the surface element added to the deionized water has reached the critical micelle concentration (CMC), and the surface element forms a microcell, leaving only the monomer to act in the solution. Figure 13 shows the relationship between surface element concentration and foaming height. Razafindralambo et al. pointed out that the lowest MD value of surface element can reach 0.10. Compared with iturin, surface element has excellent foaming effect, which is presumed to be related to the structure between the two. Surface element belongs to anionic interface activity. And its fatty acid carbon chain is shorter, while itrathecin is a nonionic surfactant with a long fatty acid carbon chain (Razafindralambo et al., 1998). The surface pigments produced by Bacillus subtilis TH have foaming ability and can be used as personal care products such as detergents, shampoos and hand lotions.

實施例八 表面素作為滑順劑Example 8 Surface element as a smoothing agent

表面素於沖洗時會表現出色的滑順感(Flushing will show good sense of smooth),而在低濃度的情況下,會產生液滴(corecervate)現象。 The surface is excellent in Flushing will show good sense of smooth, and at low concentrations, it will produce a corecervate phenomenon.

1. 表面素可降低濁度 1. Surface element can reduce turbidity

(1)把洗髮精的相對濃度調整為0.01-1.0相對濃度=洗髮精原液(g)/(洗髮精原液(g)+水(g)) (1) Adjust the relative concentration of shampoo to 0.01-1.0 relative concentration = shampoo stock solution (g) / (shampoo stock solution (g) + water (g))

(2)測定(1)溶液420ml中的透過率(%、温度40℃)、簡單地表示它的濁度(Turbidity)(%)=100-透過率(%) (2) Measurement (1) Transmittance (%, temperature: 40 ° C) in 420 ml of the solution, simply indicating its turbidity (%) = 100 - transmittance (%)

由第14圖可知,與清潔用品中常用的乳化劑-月桂醇聚醚硫酸酯鈉鹽(sodium laureth sulfate)相比較,本案之表面素更能夠降低洗髮精的濁度,意即增加洗髮精的滑順感。 It can be seen from Fig. 14 that the surface element of the present invention is more capable of reducing the turbidity of the shampoo, i.e., increasing the shampoo, compared with the sodium laurate sulfate, which is commonly used in cleaning products. Fine smoothness.

2. 表面素會產生液滴(corecervate)現象 2. Surface molecules produce droplets (corecervate)

表面素於沖洗時會表現出色的滑順感(sense of smooth),而在低濃度的情況下,會產生液滴(corecervate)現象。 Surfaces exhibit excellent sense of smoothness when rinsed, and at low concentrations, corecervate occurs.

由第15圖可以知道,在稀釋於聚合物和界面活性劑複合物(polymer-surfactant complex)後-意即液滴(corecervate)現象,含有表面素的洗髮精會有沉澱的產生;因此而減少了摩擦感(friction sensitivity),增加滑順感(sense of smooth)。 It can be seen from Fig. 15 that after dilution of the polymer-surfactant complex - meaning the corecervate phenomenon, the surface-containing shampoo will have a precipitate; therefore Reduced friction sensitivity and increased sense of smoothness.

上述實施例及圖式僅為本發明之較佳實施例而已,當不能以之限定本發明實施之範圍,即大凡依本發明申請專利範圍所作之均等變化與修飾,皆應屬本發明專利涵蓋之範圍內。 The above-mentioned embodiments and the drawings are only the preferred embodiments of the present invention, and the scope of the present invention is not limited thereto, that is, the equivalent variations and modifications of the scope of the present invention should be covered by the present invention. Within the scope.

<110> 優茂國際股份有限公司 <110> Youmao International Co., Ltd.

<120> 表面素於化妝品上之應用 <120> Surface application to cosmetics

<160> 15 <160> 15

<170> PatentIn version 3.5 <170> PatentIn version 3.5

<210> 1 <210> 1

<211> 7 <211> 7

<212> PRT <212> PRT

<213> 枯草桿菌(Bacillus subtilus) <213> Bacillus subtilus

<400> 1(L)Glu-(L)Leu-(D)Leu-(L)Val-(L)Asp-(D)Leu-(L)Leu 7 <400> 1(L)Glu-(L)Leu-(D)Leu-(L)Val-(L)Asp-(D)Leu-(L)Leu 7

<210> 2 <210> 2

<211> 24 <211> 24

<212> DNA <212> DNA

<213> 人工序列 <213> Artificial sequence

<220> <220>

<223> Mouse RSP 16-F <223> Mouse RSP 16-F

<400> 2 <400> 2

<210> 3 <210> 3

<211> 24 <211> 24

<212> DNA <212> DNA

<213> 人工序列 <213> Artificial sequence

<220> <220>

<223> Mouse RSP 16-R <223> Mouse RSP 16-R

<400> 3 <400> 3

<210> 4 <210> 4

<211> 18 <211> 18

<212> DNA <212> DNA

<213> 人工序列 <213> Artificial sequence

<220> <220>

<223> Mouse SIT1-F <223> Mouse SIT1-F

<400> 4 <400> 4

<210> 5 <210> 5

<211> 18 <211> 18

<212> DNA <212> DNA

<213> 人工序列 <213> Artificial sequence

<220> <220>

<223> Mouse SIT1-R <223> Mouse SIT1-R

<400> 5 <400> 5

<210> 6 <210> 6

<211> 21 <211> 21

<212> DNA <212> DNA

<213> 人工序列 <213> Artificial sequence

<220> <220>

<223> Human-GAPDH-F <223> Human-GAPDH-F

<400> 6 <400> 6

<210> 7 <210> 7

<211> 21 <211> 21

<212> DNA <212> DNA

<213> 人工序列 <213> Artificial sequence

<220> <220>

<223> Human-GAPDH-R <223> Human-GAPDH-R

<400> 7 <400> 7

<210> 8 <210> 8

<211> 23 <211> 23

<212> DNA <212> DNA

<213> 人工序列 <213> Artificial sequence

<220> <220>

<223> Human-SIT1-F <223> Human-SIT1-F

<400> 8 <400> 8

<210> 9 <210> 9

<211> 22 <211> 22

<212> DNA <212> DNA

<213> 人工序列 <213> Artificial sequence

<220> <220>

<223> Human-SIT1-R <223> Human-SIT1-R

<400> 9 <400> 9

<210> 10 <210> 10

<211> 20 <211> 20

<212> DNA <212> DNA

<213> 人工序列 <213> Artificial sequence

<220> <220>

<223> Human-SIT3-F <223> Human-SIT3-F

<400> 10 <400> 10

<210> 11 <210> 11

<211> 20 <211> 20

<212> DNA <212> DNA

<213> 人工序列 <213> Artificial sequence

<220> <220>

<223> Human-SIT3-R <223> Human-SIT3-R

<400> 11 <400> 11

<210> 12 <210> 12

<211> 20 <211> 20

<212> DNA <212> DNA

<213> 人工序列 <213> Artificial sequence

<220> <220>

<223> T7 <223> T7

<400> 12 <400> 12

<210> 13 <210> 13

<211> 21 <211> 21

<212> DNA <212> DNA

<213> 人工序列 <213> Artificial sequence

<220> <220>

<223> SP6* <223> SP6*

<400> 13 <400> 13

<210> 14 <210> 14

<211> 18 <211> 18

<212> DNA <212> DNA

<213> 人工序列 <213> Artificial sequence

<220> <220>

<223> Oligo d(T)* <223> Oligo d(T)*

<400> 14 <400> 14

Claims (43)

一種以表面素(surfactin)製備抗老化化妝品組合物的方法,其中該組合物係包含表面素及藥學上可接受之載劑、賦形劑、稀釋劑、輔劑等。 A method of preparing an anti-aging cosmetic composition by surfactin, wherein the composition comprises a surface element and a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, and the like. 如申請專利範圍第1項之以表面素製備抗老化化妝品組合物的方法,其中該表面素為一種環脂胜肽,該表面素包括連接至β羥基脂肪酸之七胜肽序列(L)Glu-(L)Leu-(D)Leu-(L)Val-(L)Asp-(D)Leu-(L)Leu,該表面素在脂肪酸末端之脂肪酸分布如下:(1)異C13大於3%;(2)正C13大於0.65%;(3)異C14大於17%;(4)正C14少於41%;及(5)異C15少於11%。 A method for preparing an anti-aging cosmetic composition with a surface element as claimed in claim 1, wherein the surface element is a cyclolipin peptide comprising a seven-peptide sequence (L) Glu-linked to a β-hydroxy fatty acid. (L) Leu-(D)Leu-(L)Val-(L)Asp-(D)Leu-(L)Leu, the fatty acid distribution of the surface element at the fatty acid terminal is as follows: (1) the iso C13 is greater than 3%; (2) positive C13 is greater than 0.65%; (3) iso-C14 is greater than 17%; (4) positive C14 is less than 41%; and (5) iso-C15 is less than 11%. 如申請專利範圍第2項之以表面素製備抗老化化妝品組合物的方法,其中該脂肪酸末端之脂肪酸分布如下:(1)異C13大於10%;(2)正C13大於25%;(3)異C14大於35%;(4)正C14少於25%;及(5)異C15少於3%。 A method for preparing an anti-aging cosmetic composition by surface element as claimed in claim 2, wherein the fatty acid at the terminal of the fatty acid is distributed as follows: (1) an iso C13 is greater than 10%; (2) a positive C13 is greater than 25%; (3) The iso-C14 is greater than 35%; (4) the positive C14 is less than 25%; and (5) the iso-C15 is less than 3%. 如申請專利範圍第3項之以表面素製備抗老化化妝品組合物的方法,其中該脂肪酸末端之脂肪酸分布如下:(1)異C 13為11%;(2)正C13為26%;(3)異C 14為37%;(4)正C14為24%;及(5)異C15為2%。 A method for preparing an anti-aging cosmetic composition with a surface element according to the third aspect of the patent application, wherein the fatty acid at the terminal of the fatty acid is distributed as follows: (1) an iso C 13 is 11%; (2) a positive C13 is 26%; (3) The iso C 14 is 37%; (4) the positive C14 is 24%; and (5) the iso C15 is 2%. 如申請專利範圍第1項之以表面素製備抗老化化妝品組合物的方法,其中該表面素之分子量為1022或1036Da。 A method of preparing an anti-aging cosmetic composition with a surface element as claimed in claim 1, wherein the surface element has a molecular weight of 1022 or 1036 Da. 如申請專利範圍第1項之以表面素製備抗老化化妝品組合物的方法,其中該表面素包含其化學異構物。 A method of preparing an anti-aging cosmetic composition with a surface element according to the first aspect of the patent application, wherein the surface element comprises a chemical isomer thereof. 如申請專利範圍第1項之以表面素製備抗老化化妝品組合物的方法,其中該抗老化化妝品組合物可進一步包含下列至少一者:醇類、酯類、複合多醣體、堅果油及維生素。 The method of preparing an anti-aging cosmetic composition by surface factor as claimed in claim 1, wherein the anti-aging cosmetic composition further comprises at least one of the following: an alcohol, an ester, a complex polysaccharide, a nut oil, and a vitamin. 如申請專利範圍第7項之以表面素製備抗老化化妝品組合物的方法,其中該醇類係包括下列至少一者:C16-18醇、丁二醇、戊二醇、辛二醇、丙三醇、16醇、18醇、22醇及丙二醇。 A method for preparing an anti-aging cosmetic composition by surface factor as claimed in claim 7 wherein the alcohol comprises at least one of the following: C16-18 alcohol, butanediol, pentanediol, octanediol, and C3. Alcohol, 16 alcohol, 18 alcohol, 22 alcohol and propylene glycol. 如申請專利範圍第7項之以表面素製備抗老化化妝品組合物的方法,其中該酯類係包括下列至少一者:橄欖油鯨蠟醇酯(OLIVEM 1000)、單硬脂酸甘油酯(GSM)、十四酸異丙酯(IPM)、十六酸異丙酯(IPP)及三酸甘油酯。 A method of preparing an anti-aging cosmetic composition with a surface element as claimed in claim 7 wherein the ester comprises at least one of the following: olive oil cetyl alcohol ester (OLIVEM 1000), glyceryl monostearate (GSM) ), isopropyl myristate (IPM), isopropyl palmitate (IPP) and triglyceride. 如申請專利範圍第7項之以表面素製備抗老化化妝品組合物的方法,其中該複合多醣體係包括下列至少一者:漢生膠、銀耳多醣體、葡聚多醣體、狹葉番瀉籽多醣體。 The method for preparing an anti-aging cosmetic composition by surface element according to the seventh aspect of the patent application, wherein the composite polysaccharide system comprises at least one of the following: xanthan gum, tremella polysaccharide, glucoside polysaccharide, senna seed polysaccharide . 如申請專利範圍第7項之以表面素製備抗老化化妝品組合物的方法,其中該堅果油係包括下列至少一者:阿甘油、夏威夷核果油、酪梨油、小麥胚芽油、橄欖油。 A method of preparing an anti-aging cosmetic composition with a surface element according to the seventh aspect of the patent application, wherein the nut oil comprises at least one of the following: arganic acid, Hawaiian nuclear oil, avocado oil, wheat germ oil, olive oil. 如申請專利範圍第7項之以表面素製備抗老化化妝品組合物的方法,其中該維生素係包括下列至少一者:維生素A、維生素B、維生素C、 維生素E、維生素F、維生素K。 A method for preparing an anti-aging cosmetic composition with a surface element according to the seventh aspect of the patent application, wherein the vitamin system comprises at least one of the following: vitamin A, vitamin B, vitamin C, Vitamin E, vitamin F, vitamin K. 如申請專利範圍第1項之以表面素製備抗老化化妝品組合物的方法,其中該抗老化化妝品組合物係用以促進纖維母細胞之增殖、膠原蛋白的增生或sertuin 1基因的表現。 A method for preparing an anti-aging cosmetic composition by surface factor as claimed in claim 1, wherein the anti-aging cosmetic composition is for promoting proliferation of fibroblasts, proliferation of collagen, or expression of a sertuin 1 gene. 如申請專利範圍第1項之以表面素製備抗老化化妝品組合物的方法,其中該抗老化化妝品組合物係用以抗紫外光老化或抗氧化。 A method of preparing an anti-aging cosmetic composition with a surface element according to the first aspect of the patent application, wherein the anti-aging cosmetic composition is used for anti-UV aging or anti-oxidation. 如申請專利範圍第1項之以表面素製備抗老化化妝品組合物的方法,其中該抗老化化妝品組合物係用以抑制基質金屬蛋白酶(Matrix metallopeptidase)。 A method of preparing an anti-aging cosmetic composition with a surface element as claimed in claim 1, wherein the anti-aging cosmetic composition is for inhibiting matrix metallopeptidase. 如申請專利範圍第15項之以表面素製備抗老化化妝品組合物的方法,其中該基質金屬蛋白酶為基質金屬蛋白酶九型(Matrix metallopeptidase 9)。 A method for preparing an anti-aging cosmetic composition with a surface element according to the fifteenth aspect of the patent application, wherein the matrix metalloproteinase is Matrix metallopeptidase 9 (Matrix metallopeptidase 9). 一種以表面素(surfactin)製備增加皮膚穿透力之組合物的方法,其中該組合物係包含表面素及藥學上可接受之載劑、賦形劑、稀釋劑、輔劑等。 A method of preparing a composition for increasing skin penetration by surfactin, wherein the composition comprises a surface element and a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, and the like. 如申請專利範圍第17項之以表面素製備增加皮膚穿透力之組合物的方法,其中該表面素為一種環脂胜肽,該表面素包括連接至β羥基脂肪酸之七胜肽序列(L)Glu-(L)Leu-(D)Leu-(L)Val-(L)Asp-(D)Leu-(L)Leu,該表面素在脂肪酸末端之脂肪酸分布如下:(1)異C13大於3%;(2)正C13大於0.65%;(6)異C14大於17%;(7)正C14少於41%;及 (8)異C15少於11%。 A method for preparing a composition for increasing skin penetration by a surface element according to claim 17, wherein the surface element is a cyclolipopeptide comprising a seven-peptide sequence linked to a beta hydroxy fatty acid (L) Glu-(L)Leu-(D)Leu-(L)Val-(L)Asp-(D)Leu-(L)Leu, the fatty acid distribution of the surface element at the fatty acid terminal is as follows: (1) the hetero-C13 is greater than 3%; (2) positive C13 is greater than 0.65%; (6) iso C14 is greater than 17%; (7) positive C14 is less than 41%; (8) The difference of C15 is less than 11%. 如申請專利範圍第18項之以表面素製備增加皮膚穿透力之組合物的方法,其中該脂肪酸末端之脂肪酸分布如下:(1)異C13大於10%;(2)正C13大於25%;(3)異C14大於35%;(4)正C14少於25%;及(5)異C15少於3%。 A method for preparing a composition for increasing skin penetration by a surface element according to claim 18, wherein the fatty acid at the terminal of the fatty acid is distributed as follows: (1) an iso C13 is greater than 10%; and (2) a positive C13 is greater than 25%; (3) The iso-C14 is greater than 35%; (4) the positive C14 is less than 25%; and (5) the iso-C15 is less than 3%. 如申請專利範圍第19項之以表面素製備增加皮膚穿透力之組合物的方法,其中該脂肪酸末端之脂肪酸分布如下:(1)異C 13為11%;(2)正C13為26%;(3)異C 14為37%;(4)正C14為24%;及(5)異C15為2%。 A method for preparing a composition for increasing skin penetration by a surface element according to claim 19, wherein the fatty acid at the terminal of the fatty acid is distributed as follows: (1) an iso C 13 is 11%; and (2) a positive C13 is 26%. (3) Iso C 14 is 37%; (4) C14 is 24%; and (5) Iso C15 is 2%. 如申請專利範圍第17項之以表面素製備增加皮膚穿透力之組合物的方法,其中該表面素之分子量為1022或1036Da。 A method of preparing a composition for increasing skin penetration by a surface element as claimed in claim 17, wherein the surface element has a molecular weight of 1022 or 1036 Da. 如申請專利範圍第17項之以表面素製備增加皮膚穿透力之組合物的方法,其中該表面素包含其化學異構物。 A method of preparing a composition for increasing skin penetration by a surface element, as in claim 17, wherein the surface element comprises a chemical isomer thereof. 如申請專利範圍第17項之以表面素製備增加皮膚穿透力之組合物的方法,其中該增加皮膚穿透力之組合物可進一步包含下列至少一者:醇類、酯類、複合多醣體、堅果油及維生素。 A method for preparing a composition for increasing skin penetration by a surface element according to claim 17, wherein the composition for increasing skin penetration further comprises at least one of the following: an alcohol, an ester, a complex polysaccharide. , nut oil and vitamins. 如申請專利範圍第23項之以表面素製備增加皮膚穿透力之組合物的方法,其中該醇類係包括下列至少一者:C16-18醇、丁二醇、戊二醇、辛二醇、丙三醇、16醇、18醇、22醇及丙二醇。 A method for preparing a composition for increasing skin penetration by a surface element according to the scope of claim 23, wherein the alcohol comprises at least one of the following: C16-18 alcohol, butanediol, pentanediol, octanediol , glycerol, 16 alcohol, 18 alcohol, 22 alcohol and propylene glycol. 如申請專利範圍第23項之以表面素製備增加皮膚穿透力之組合物的方法,其中該酯類係包括下列至少一者:橄欖油鯨蠟醇酯(OLIVEM 1000)、單硬脂酸甘油酯(GSM)、十四酸異丙酯(IPM)、十六酸異丙酯(IPP)及三酸甘油酯。 A method of preparing a composition for increasing skin penetration by a surface element according to claim 23, wherein the ester comprises at least one of the following: olive oil cetyl alcohol ester (OLIVEM 1000), glyceryl monostearate Ester (GSM), isopropyl myristate (IPM), isopropyl palmitate (IPP) and triglycerides. 如申請專利範圍第23項之以表面素製備增加皮膚穿透力之組合物的方法,其中該複合多醣體係包括下列至少一者:漢生膠、銀耳多醣體、葡聚多醣體、狹葉番瀉籽多醣體。 A method for preparing a composition for increasing skin penetration by a surface element according to claim 23, wherein the composite polysaccharide system comprises at least one of the following: xanthan gum, tremella polysaccharide, glucoside polysaccharide, senna Seed polysaccharide. 如申請專利範圍第23項之以表面素製備增加皮膚穿透力之組合物的方法,其中該堅果油係包括下列至少一者:阿甘油、夏威夷核果油、酪梨油、小麥胚芽油、橄欖油。 A method for preparing a composition for increasing skin penetration by a surface element according to the scope of claim 23, wherein the nut oil comprises at least one of the following: argan oil, Hawaiian stone oil, avocado oil, wheat germ oil, olive oil. 如申請專利範圍第23項之以表面素製備增加皮膚穿透力之組合物的方法,其中該維生素係包括下列至少一者:維生素A、維生素B、維生素C、維生素E、維生素F、維生素K。 A method for preparing a composition for increasing skin penetration by a surface element according to claim 23, wherein the vitamin comprises at least one of the following: vitamin A, vitamin B, vitamin C, vitamin E, vitamin F, vitamin K . 如申請專利範圍第17項之以表面素製備增加皮膚穿透力之組合物的方法,其中該組合物係用以促進化妝品原料穿透皮膚。 A method of preparing a composition for increasing skin penetration by a surface element, as in claim 17, wherein the composition is for promoting penetration of a cosmetic material into the skin. 如申請專利範圍第29項之以表面素製備增加皮膚穿透力之組合物的方法,其中該化妝品原料為皮質類固醇(dexamethasone)。 A method of preparing a composition for increasing skin penetration by a surface element according to claim 29, wherein the cosmetic material is dexamethasone. 如申請專利範圍第29項之以表面素製備增加皮膚穿透力之組合物的方法,其中該化妝品原料為玻尿酸(hyaluronic acid)。 A method of preparing a composition for increasing skin penetration by a surface element according to claim 29, wherein the cosmetic material is hyaluronic acid. 如申請專利範圍第29項之以表面素製備增加皮膚穿透力之組合物的方法,其中該化妝品原料為聚麩胺酸(Gamma-polyglutamic acid)。 A method of preparing a composition for increasing skin penetration by a surface element according to claim 29, wherein the cosmetic material is gamma-polyglutamic acid. 如申請專利範圍第29項之以表面素製備增加皮膚穿透力之組合物的方 法,其中該化妝品原料為奈米金(gold-nanoparticles)。 A method for preparing a composition for increasing skin penetration by using a surface element as claimed in claim 29 The method wherein the cosmetic material is gold-nanoparticles. 一種以表面素(surfactin)製備乳化劑組合物的方法,其中該組合物係包含表面素及藥學上可接受之載劑、賦形劑、稀釋劑、輔劑等。 A method of preparing an emulsifier composition by surfactin, wherein the composition comprises a surface element and a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, and the like. 如申請專利範圍第34項之以表面素製備乳化劑組合物的方法,其中該表面素為一種環脂胜肽,該表面素包括連接至β羥基脂肪酸之七胜肽序列(L)Glu-(L)Leu-(D)Leu-(L)Val-(L)Asp-(D)Leu-(L)Leu,該表面素在脂肪酸末端之脂肪酸分布如下:(1)異C13大於3%;(2)正C13大於0.65%;(9)異C14大於17%;(10)正C14少於41%;及(11)異C15少於11%。 A method for preparing an emulsifier composition by a surface element according to claim 34, wherein the surface element is a cyclolipin peptide comprising a seven-peptide sequence (L) Glu- (linked to a β-hydroxy fatty acid). L) Leu-(D)Leu-(L)Val-(L)Asp-(D)Leu-(L)Leu, the fatty acid distribution of the surface element at the fatty acid terminal is as follows: (1) the iso-C13 is greater than 3%; 2) positive C13 is greater than 0.65%; (9) iso-C14 is greater than 17%; (10) positive C14 is less than 41%; and (11) iso-C15 is less than 11%. 如申請專利範圍第35項之以表面素製備乳化劑組合物的方法,其中該脂肪酸末端之脂肪酸分布如下:(1)異C13大於10%;(2)正C13大於25%;(3)異C14大於35%;(4)正C14少於25%;及(5)異C15少於3%。 A method for preparing an emulsifier composition by a surface element according to claim 35, wherein the fatty acid at the terminal of the fatty acid is distributed as follows: (1) an iso C13 is greater than 10%; (2) a positive C13 is greater than 25%; (3) C14 is greater than 35%; (4) positive C14 is less than 25%; and (5) iso-C15 is less than 3%. 如申請專利範圍第36項之以表面素製備乳化劑組合物的方法,其中該脂肪酸末端之脂肪酸分布如下:(1)異C 13為11%;(2)正C13為26%;(3)異C 14為37%;(4)正C14為24%;及(5)異C15為2%。 A method for preparing an emulsifier composition by a surface element according to claim 36, wherein the fatty acid at the terminal of the fatty acid is distributed as follows: (1) 11% of iso C 13; (2) 26% of positive C13; (3) The iso C 14 is 37%; (4) the positive C14 is 24%; and (5) the iso C15 is 2%. 如申請專利範圍第34項之以表面素製備乳化劑組合物的方法,其中該表面素之分子量為1022或1036Da。 A method of preparing an emulsifier composition by a surface element according to claim 34, wherein the surface element has a molecular weight of 1022 or 1036 Da. 如申請專利範圍第34項之以表面素製備乳化劑組合物的方法,其中該表面素包含其化學異構物。 A method of preparing an emulsifier composition by a surface element as claimed in claim 34, wherein the surface element comprises a chemical isomer thereof. 如申請專利範圍第34項之以表面素製備乳化劑組合物的方法,其中該乳化劑組合物可進一步包含下列至少一者:脂肪酸甘油酯、脂肪酸山梨醇酐酯、脂肪酸蔗糖酯、脂肪酸丙二醇酯、卵磷脂。 A method for preparing an emulsifier composition by a surface element according to claim 34, wherein the emulsifier composition further comprises at least one of the following: a fatty acid glyceride, a fatty acid sorbitan ester, a fatty acid sucrose ester, a fatty acid propylene glycol ester. , lecithin. 如申請專利範圍第34項之以表面素製備乳化劑組合物的方法,其中該乳化劑組合物係用以增加起泡力。 A method of preparing an emulsifier composition by a surface element as claimed in claim 34, wherein the emulsifier composition is for increasing the foaming power. 如申請專利範圍第34項之以表面素製備乳化劑組合物的方法,其中該乳化劑組合物係用以增加乳化作用。 A method of preparing an emulsifier composition by a surface element as claimed in claim 34, wherein the emulsifier composition is used to increase emulsification. 如申請專利範圍第34項之以表面素製備乳化劑組合物的方法,其中該乳化劑組合物係用以增加滑順感。 A method of preparing an emulsifier composition by a surface element as claimed in claim 34, wherein the emulsifier composition is used to increase slipperiness.
TW103122443A 2014-06-30 2014-06-30 The Application of Surface to Cosmetics TWI580440B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
TW103122443A TWI580440B (en) 2014-06-30 2014-06-30 The Application of Surface to Cosmetics
CN201510369154.2A CN105213210B (en) 2014-06-30 2015-06-29 Use of surfactin in cosmetics

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW103122443A TWI580440B (en) 2014-06-30 2014-06-30 The Application of Surface to Cosmetics

Publications (2)

Publication Number Publication Date
TW201600118A true TW201600118A (en) 2016-01-01
TWI580440B TWI580440B (en) 2017-05-01

Family

ID=54982738

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103122443A TWI580440B (en) 2014-06-30 2014-06-30 The Application of Surface to Cosmetics

Country Status (2)

Country Link
CN (1) CN105213210B (en)
TW (1) TWI580440B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111773155A (en) * 2020-07-10 2020-10-16 陕西慧康生物科技有限责任公司 Stable peptide containing active matter from fermentation source

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101786914B1 (en) * 2017-01-31 2017-11-15 주식회사 삼양사 Adhesive elastic band for skin-lifting or enhancement of skin elasticity
CN106691946A (en) * 2017-02-11 2017-05-24 佛山市芊茹化妆品有限公司 Anti-glycation facial mask
TWI627185B (en) * 2017-06-19 2018-06-21 劉玉春 Anti-aging peptide, its composition and method of using the same
CN108271776B (en) * 2017-12-25 2021-06-11 武汉科诺生物科技股份有限公司 Use of bacillus lipopeptide metabolite as microbial agent aid

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7981M (en) * 1967-10-21 1970-06-08
IT1254918B (en) * 1992-04-24 1995-10-11 Eniricerche Spa ISOLATION AND CHARACTERIZATION OF THE SFP GENE OF BACILLUS SUBTILIS
CN1196469C (en) * 1998-05-29 2005-04-13 昭和电工株式会社 Surfactant for use in external preparations for skin and external preparation for skin containing the same
US20040219125A1 (en) * 2001-08-10 2004-11-04 Tadashi Yoneda Oily thickened gel-like composition, emulsified composition using the composition and preparation method thereof
JP2003128512A (en) * 2001-10-18 2003-05-08 Showa Denko Kk Antibacterial composition for cosmetic
JP2005162741A (en) * 2003-11-10 2005-06-23 Showa Denko Kk Method for producing oily thickened gel-like composition and cosmetic
US20080311234A1 (en) * 2004-03-24 2008-12-18 Tadashi Yoneda Oil-in-Water Emulsified Composition, and External Preparation for Skin and Cosmetics Using the Composition
TW200927764A (en) * 2007-09-30 2009-07-01 Umo Inc Co Ltd Peptide having antimicrobial and/or biosurfactant property
KR101608687B1 (en) * 2009-07-31 2016-04-05 (주)아모레퍼시픽 Cosmetic composition containing cyclic lipopeptide for antioxidant and antiaging

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111773155A (en) * 2020-07-10 2020-10-16 陕西慧康生物科技有限责任公司 Stable peptide containing active matter from fermentation source
CN111773155B (en) * 2020-07-10 2022-11-04 陕西慧康生物科技有限责任公司 Active matter stabilizing peptide containing fermentation source

Also Published As

Publication number Publication date
TWI580440B (en) 2017-05-01
CN105213210B (en) 2018-06-19
CN105213210A (en) 2016-01-06

Similar Documents

Publication Publication Date Title
US9364413B2 (en) Method for anti-aging treatment by surfactin in cosmetics via enhancing sirtuin
CA2579888C (en) Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same
TWI580440B (en) The Application of Surface to Cosmetics
US8859021B2 (en) Skin appearance through gene manipulation
CN106924216A (en) Nanoparticulate compositions, its preparation and their purposes
CN105007990B (en) The purposes of cosmetic composition from fish artemia hatching solution, its production method and its aesthetic appearance for being used to improving skin
CN113874044B (en) Skin composition
KR101841118B1 (en) Composition for skin external application comprising extract of scenedesmus sp.
CN101132804A (en) Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same
CN109640974A (en) Amide derivatives, the preparation method and use of more coffee acyl chinic acids
RU2370275C2 (en) Method of cosmetic and age skin defect treatment (correction) at combined application of fraction photothermolysis technology with bioactive ingredients independently of administration method
ES2926378T3 (en) Compounds to prevent and treat skin or mucous membrane conditions that have an inflammatory component
JP6656890B2 (en) Filaggrin production promoter
KR20120058830A (en) Cosmetic composition for promoting the stemness of adipose-derived stem cell and proliferating skin cell containing hypericum extracts
Proietti et al. Efficacy and Tolerability of a Microneedling Device plus Exosomes for Treating melasma
Le et al. Investigating the Anti-Aging Effects of Caviar Oil on Human Skin
Sandeep A Comparative Study to Evaluate the Efficacy of Asthisrinkala Lepa and Thriphala Mashi with Pracchanna in the Management of Indraluptha wsr to Alopecia Areata
JP2023504461A (en) Peptides and compositions for use in cosmetics and pharmaceuticals
ES2645535T3 (en) Topical compositions to treat inflammatory disorders, diseases and ailments
JP2020147546A (en) Cxcr4 production inhibitory composition
TW200413013A (en) Anti-aging cosmetics comprising chemokine